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I. INTRODUCTION
Recent scientific breakthroughs have enabled the development of a
new class of human therapies that harness a patient’s own cells to
achieve therapeutic results. One of the most promising of these is an
immunotherapy that utilizes chimeric antigen receptor T-cells (CAR-
T) to enhance a patient’s ability to combat tumor cells.
1
Other
promising types of gene therapy can replace a defective copy of a
patient’s gene with a modified gene that is inserted into the patient’s
cells.
2
Researchers continue to explore stem cell treatments that will
make use of regenerative pluripotent stem cells harvested from a
patient’s body.
While treatments such as these have been discussed for years, it is
only recently that regulatory agencies have begun to approve them for
use in human patients. In 2017, the U.S. Food and Drug
Administration (FDA) approved the first two CAR-T therapies for use
in the United States: Novartis’s Kymriah (tisagenlecleucel)
3
and
Kite/Gilead’s Yescarta (axicabtagene ciloleucel),
4
both of which are
indicated for blood-based cancers (lymphoblastic leukemia and B-cell
lymphoma, respectively). European and Canadian approval of these
treatments followed in 2018.
5
While these new therapies have the potential to save and drastically
improve human life, their announced prices have also set new records.
Kymriah reportedly costs US $475,000 per treatment,
6
and Yescarta
1. See, e.g., Denise Grady, F.D.A. Approves First Gene-Altering Leukemia
Treatment, Costing $475,000, N.Y. TIMES (Aug. 30, 2017),
https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html (describing
the University of Pennsylvania researchers’ treatment using the CAR-T cell
therapy).
2. Gina Kolata, New Gene-Therapy Treatments Will Carry Whopping Price
Tags, N.Y. TIMES (Sept. 11, 2017), https://www.nytimes.com/2017/09/11/health/
cost-gene-therapy-drugs.html.
3. See U.S. FOOD & DRUG ASS’N, BL 125646/0, BIOLOGICS LICENSE
APPLICATION APPROVAL LETTER FOR NOVARTIS PHARMACEUTICALS 1 (Aug. 30,
2017) [hereinafter NOVARTISAPPROVAL LETTER].
4. See U.S. FOOD & DRUG ASS’N, BL 125643/0, BIOLOGICS LICENSE
APPLICATION APPROVAL LETTER FOR KITE PHARMA 1 (Oct. 18, 2017) [hereinafter
KITEAPPROVAL LETTER].
5. See discussion infra Section I.B.3 (discussing regulatory approvals).
6. Kolata, supra note 2.
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will be priced at US$373,000.
7
And recently Novartis announced that
$4–5 million per patient would be a “cost effective” price for a gene
therapy under development for spinal muscular atrophy (SMA).
8
These high price tags portend a large and highly lucrative market
ahead for CAR-T and similar therapies. One market analyst predicts
that the global CAR-T market will expand from $168 million in 2018
to $8 billion in 2028.
9
Given the high profits anticipated from these novel therapies, it is
not surprising that the firms developing them have sought patents
covering many aspects of their manufacture, composition, and use.
10
However, unlike new small molecule drugs and biologics, these
therapies are not novel compounds or biological entities but modified
versions of a patient’s own cells.
11
As such, one must ask whether
therapies such as Kymriah and Yescarta are drugs, as their
manufacturers characterize them, or methods of medical treatment.
The distinction is a crucial one, as the laws of more than eighty
countries around the world prohibit the patenting of methods of
medical treatment, and even countries such as the United States,
Canada, and Australia, which do not expressly prohibit such patents,
may significantly limit the scope of patenting and enforcement.
12
In this article we ask whether therapies that act primarily to alter a
7. Deena Beasley, U.S. Medicare Sets Outpatient Rate for Yescarta
Reimbursement, REUTERS (Apr. 5, 2018), https://www.reuters.com/article/us-
cancer-medicare-yescarta/u-s-medicare-sets-outpatient-rate-for-yescarta-
reimbursement-idUSKCN1HC2N3.
8. John Miller, Novartis Says SMA Gene Therapy is Cost-Effective At $4-5 Mln
Per Patient, REUTERS (Nov. 5, 2018), https://www.reuters.com/article/novartis-
gene-therapy/novartis-says-sma-gene-therapy-is-cost-effective-at-4-5-mln-per-
patient-idUSFWN1XG0OD.
9. Jeannie Baumann, Breakthrough Cancer Therapy Stalls in Manufacturing
Bottleneck, BLOOMBERG LAWNEWS, Feb. 12, 2019.
10. See discussion infra Section II (discussing patent coverage).
11. See Grady, supra note 1 (stating that these treatments “turn patient’s cells
into a ‘living drug’”).
12. See Paul Mazzola, Primer on Patenting Methods of Medical Treatment in
the United States and Abroad, HEALIO (Aug. 4, 2017), https://www.healio.com/
orthopedics/business-of-orthopedics/news/online/%7B9b2e4d7f-e2b1-4be9-a728-7
bccf1dc0a3b%7D/primer-on-patenting-methods-of-medical-treatment-in-the-
united-states-and-abroad (highlighting Australia, Canada, and Europe’s
patentability limitations on methods of human therapy treatments).
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patient’s own cells, particularly CAR-T therapies such as Kymriah and
Yescarta, should be considered methods of medical treatment that are
largely ineligible for patent protection around the world and, if so, how
national patent offices, legislatures, and courts should respond.
13
The
remainder of this article proceeds in four principal Parts as follows:
Part I provides an overview of the scientific and regulatory
background of CAR-T and other gene and cell therapies such as
Kymriah and Yescarta. Part II describes the patenting exclusion for
methods of medical treatment around the world. Part III analyzes the
degree to which CAR-T and other gene and cell therapies should be
considered methods of medical treatment that are ineligible for patent
protection, or subject to limitations on patent protection. And Part IV
considers the implications of the potential loss of patentability on the
development and market for such therapies, as well as potential
governmental reactions.
II. CAR-T AND GENETIC THERAPIES
While a number of different therapy types make use of a patient’s
cells, we focus in this article on CAR-T therapies, both because they
present a clear case for characterization as therapeutic methods and
because there are multiple CAR-T therapies that have received
regulatory approval and are now being administered to human
patients.
14
A. OVERVIEW OFCAR-T THERAPY
Broadly speaking, CAR-T therapies involve the modification of a
patient’s T-lymphocytes (white blood cells that play a key role in the
13. But see Jacob S. Sherkow, Patricia J. Zettler, and Henry T. Greely, Is It
‘Gene Therapy’?, J.L. BIOSCI. (2018) (“[A]ll therapies, in some sense, affect a
patient’s genes, whether it’s through altering transcription, regulating translation, or
even modifying the epigenome. A relaxing vacation—sun, surf, and sangria—
arguably does more to regulate gene expression than many ‘precision’ therapies.”).
14. See, e.g., NCI Staff, With Federal Approval for Advanced Lymphoma,
Second CAR T-Cell Therapy Moves to the Clinic, NAT’L CANCER INST. (Oct. 25,
2017), https://www.cancer.gov/news-events/cancer-currents-blog/2017/yescarta-
fda-lymphoma (stating that the Food and Drug Administration approved the use of
“axicabtagene ciloleucel (Yescarta™)” in treating patients with large-B-cell
lymphomas).
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immune system) so as to target particular forms of tumor cells.
15
An
overview of the CAR-T treatment process is illustrated in Figure 1
(note its characterization as a “cell manufacturing” process by the
vendor).
Figure 1 – Overview of CAR-T cell manufacturing process
16
As shown in Figure 1, the first stage of CAR-T treatment is the
extraction of T-cells from a patient’s body through a procedure known
as leukapheresis.
17
While leukapheresis is performed on site at the
patient’s healthcare facility, extracted cells are sent to a centralized
laboratory (in the case of Kymriah, a Novartis’s facility in either
Morris Plains, New Jersey or Fraunhofer, Germany).
18
Because
leukapheresis collects multiple cell types in a mixture that may vary
based on the patient’s disease stage, genetics, age, and treatment
history, the collected cellular material must be processed to reduce
these impurities.
19
If insufficient T-cells remain, T-cell enrichment
15. See id.
16. U.S. FOOD & DRUG ASS’N, BLA 125646, FDA BRIEFING DOCUMENT:
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 14 (2017) [hereinafter FDA
BRIEFING FORNOVARTIS].
17. Id. at 18.
18. See id. at 43.
19. See id. at 18.
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steps may be necessary.
20
Once the patient’s T-cells are collected and processed, they are
treated with synthetic antigen receptors (CARs) that are known to bind
to particular proteins expressed on the surface of tumor cells.
21
In the
case of Kymriah, the target protein is known as CD19, which is
expressed on the surface of B cell tumors.
22
A retroviral vector then
introduces the synthetic CAR to the patient’s T-cells.
23
In some cases,
the vector may be inserted into the T-cell using a gene editing
technique such as CRISPR-Cas9.
24
The modified T-cells, which the
manufacturer refers to as its “product,” are then reintroduced to the
patient’s bloodstream at the healthcare facility.
25
In the patient’s body, the modified T-cells are attracted to tumor
cells by means of their new antigen receptors.
26
Once a modified T-
cell comes into proximity with a tumor cell, it attacks the tumor by
releasing toxic granules (cytotoxicity) or by signaling other cells to
attack the tumor (cytokine signaling).
27
These mechanisms are
illustrated in Fig. 2 and have proven to be clinically efficacious.
28
Novartis reported a complete remission rate of 82.5% six months after
Kymriah was administered in a Phase II single-arm multicenter trial
in pediatric patients with relapsed or refractory B-cell acute
lymphoblastic leukemia.
29
20. Id.
21. Id. at 14. See generally Carl H. June & Michael Sadelain, Chimeric Antigen
Receptor Therapy, 379 N. ENG. J. MED. 64 (2018) (providing an overview of the
technology).
22. Id. at 16.
23. See id. at 17; see also Justin Eyquem et al., Targeting a CAR to the TRAC
Locus with CRISPR/Cas9 Enhances Tumour Rejection, 543 NATURE 113, 113
(2017).
24. Eyquem et al., supra note 23, at 113.
25. FDABRIEFING FORNOVARTIS, supra note 166, at 1, 8, 9.
26. Id. at 17.
27. Id. at 17–18.
28. Id. at 15.
29. Id. at 8.
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Figure 2 – Tisagenlecleucel mechanisms of action
30
B. REGULATORYAPPROVAL OFGENE AND CELL THERAPIES
1. U.S. Regulatory Framework for Gene Therapies
In the United States, gene and cell therapies are regulated as
biological products, or biologics, under the Public Health Service Act
(PHSA)
31
and the Federal Food, Drug, and Cosmetic Act (FDCA).
32
An applicant seeking approval to market and distribute a new biologic
in the United States must complete preclinical laboratory tests, animal
studies, and formulation studies as well as human clinical trials to
establish the safety, potency, and purity of the product candidate for
30. Id. at 15.
31. See Public Health Service Act, 42 U.S.C. § 262 (2017) (establishing the
procedures for the issuance of biologics licenses).
32. See Federal Food, Drug, & Cosmetic Act, 21 U.S.C. § 301 (2017)
(authorizing the FDA to generally oversee the safety of food, drugs, medical devices,
and cosmetics in the United States).
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each proposed indication.
33
In addition, the FDA defines a “gene therapy product” as a product
that operates by transcription and/or translation of transferred genetic
material and/or by integrating into the host genome, and which is
administered using nucleic acids, viruses, or genetically engineered
microorganisms.
34
Gene therapy products may be used to modify cells
in vivo or transferred to cells ex vivo prior to administration to the
recipient.
35
The FDA and the NIH have published guidance documents
with respect to the development and submission of protocols for gene
therapy products that provide additional factors that the FDA will
consider at each stage of development.
36
In order to obtain marketing approval for a new gene therapy
product, an applicant must submit a Biologics License Application
(BLA) to the FDA requesting marketing approval for one or more
proposed indications, including detailed information on the
manufacture and composition of the product and its proposed
labeling.
37
The BLA must contain extensive manufacturing
information and detailed information on the composition of the
product and its proposed labeling.
38
As part of its BLA review, the FDA will inspect the manufacturing
facilities at which the proposed product and its components will be
produced to assess compliance with the FDA’s current Good
Manufacturing Practices (cGMP) requirements and to assure that the
33. U.S. FOOD & DRUG ASS’N, CHEMISTRY, MANUFACTURING, AND CONTROL
(CMC) INFORMATION FOR HUMAN GENE THERAPY INVESTIGATIONAL NEW DRUG
APPLICATIONS (INDS) 1–2 (2018) [hereinafter INDS INFORMATION] (“This guidance
applies to human gene therapy products and to combination products that contain a
human gene therapy in combination with a drug or device.”).
34. U.S. FOOD & DRUG ASS’N, GUIDANCE FOR INDUSTRY: GENE THERAPY
CLINICALTRIALS –OBSERVING SUBJECTS FORDELAYEDADVERSE EVENTS 4 (2006)
[hereinafter FDA GENE THERAPY GUIDANCE] (defining gene therapy products as
“[a]ll products that mediate their effects by transcription and/or translation of
transferred genetic material and/or by integrating into the host genome and that are
administered as nucleic acids, viruses, or genetically engineered microorganisms”).
See generally Sherkow et al, supra note 13 (overview of FDA’s attempts to define
“gene therapy”).
35. Id.
36. See id. at 8.
37. 21 C.F.R. § 601.2(a) (2018).
38. Id.
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facilities, methods, and controls are adequate to preserve the product’s
identity, strength, quality, and purity.
39
In addition, when human
cellular and tissue products are involved, the FDA will assess the
applicant’s compliance with the FDA’s Current Good Tissue Practices
(CGTP), which seek to ensure that cell and tissue based products are
manufactured in a manner designed to prevent the introduction,
transmission, and spread of communicable disease.
40
The FDA may approve a BLA if it determines that the proposed
biologic product is safe, pure, and potent and the facility where the
product will be manufactured meets all required standards.
41
Upon
approval of a BLA, the FDA may issue an approval letter or a
complete response letter.
42
An approval letter authorizes commercial
marketing of the product with specific prescribing information for
specific indications.
43
If the application is not approved, the FDA will
issue a complete response letter, which will contain the conditions that
must be met in order to secure final approval of the application, and
when possible will outline recommended actions the sponsor might
take to obtain approval of the application.
44
2. EU Regulatory Framework for Gene Therapies
The process governing approval of medicinal products in the
European Union is similar to that in the United States. It entails
satisfactory completion of preclinical studies and adequate and well-
controlled clinical trials to establish the safety and efficacy of the
product for each proposed indication.
45
In order to receive marketing
approval for a new product in the EU, an applicant must submit a
39. Id. § 606.40.
40. U.S. FOOD & DRUG ASS’N, GUIDANCE FOR INDUSTRY: CURRENT GOOD
TISSUE PRACTICE (CGTP) AND ADDITIONAL REQUIREMENTS FORMANUFACTURERS
OF HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS
(HCT/PS) 3 (2011) [hereinafter FDAGOOD TISSUE PRACTICEGUIDANCE].
41. § 610.9(a)-(b) (outlining the requirements for the modification of a test
method or manufacturing process).
42. 21 C.F.R. § 601.3(a) (2018).
43. Drugs@FDA Glossary, U.S. FOOD & DRUG ADMIN.,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page
(last accessed Mar. 30, 2019).
44. § 601.3(a)(2).
45. Council Regulation 2017/745, 2017 O.J. (L 117) 1, 1–2 (EU).
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marketing authorization application (MAA) under a centralized
procedure administered by the European Medicines Agency (EMA).
46
The marketing of products containing viable human tissues or cells
such as gene therapy medicinal products is governed by Regulation
(EC) No 1394/2007 on advanced therapy medicinal products, read in
combination with Directive 2001/83/EC of the European Parliament
and of the Council, commonly known as the Community code on
medicinal products.
47
Regulation (EC) No 1394/2007 establishes
specific rules concerning the authorization, supervision, and
pharmacovigilance of “gene therapy medicinal products”, “somatic
cell therapy medicinal products”, and “tissue engineered products.”
48
Manufacturers of such advanced therapy “medicinal products” must
demonstrate their quality, safety, and efficacy to EMA, which renders
an opinion regarding the application for marketing authorization.
49
The European Commission then grants or refuses marketing
authorization in light of the opinion delivered by EMA.
50
We note
however that the characterization of gene and cell therapies as a
“product”, as the in the Directive 2001/83/EC which uses phrases such
as “somatic cell therapy medicinal products,” is largely a fiction. Here
the “product” in question is a batch of the patient’s own cells that are
taken from the patient, altered, and then re-introduced into the
patient’s body. We discuss this further in Part III.B, below.
3. Recent CAR-T Regulatory Approvals
The first applicant to seek U.S. regulatory marketing approval for a
CAR-T candidate therapy appears to have been Juno Therapeutics, a
leader in CAR-T research.
51
Juno’s JCAR015 therapy was jointly
developed with Cellgene and targeted Adult B-cell acute
46. Id. at 2, 13 (“[T]he Commission should ensure an appropriate level of
consultation of the European Medicines Agency (EMA), the European Chemicals
Agency and the European Food Safety Authority.”).
47. Council Regulation 1394/2007, 2007 O.J. (L 324) 121 (EC); Council
Directive 2001/83/EC, 2001 O.J. (L 311) 67 (EC).
48. Council Regulation 1394/2007, supra note 47, at 121.
49. Id. at 122, 124.
50. Id.
51. Alex Lash, After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy,
XCONOMY (Mar. 1, 2017), https://xconomy.com/seattle/2017/03/01/after-trial-
deaths-juno-pivots-and-scraps-lead-car-t-therapy/.
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lymphoblastic leukemia (ALL).
52
But despite early promise, the FDA
halted Juno’s JCAR015 Phase II trial in March 2017 after five patient
deaths resulting from cerebral edema.
53
Juno is reportedly in clinical
trials for one or more additional CAR-T based therapies.
54
Novartis received U.S. market approval for Kymriah
(tisagenlecleucel) on August 30, 2017.
55
This approval authorizes
Kymriah as “a CD19-directed genetically modified autologous T cell
immunotherapy indicated for the treatment of patients up to 25 years
of age with B-cell precursor acute lymphoblastic leukemia (ALL) that
is refractory or in second or later relapse.”
56
Because of the pediatric
indication for which Kymriah was approved, Novartis also received a
transferable, salable “rare pediatric disease priority review voucher”
under Section 529 of the Food, Drug, & Cosmetic Act.
57
Because the
indication for which Kymriah’s market approval was sought affects
fewer than 200,000 individuals in the U.S., Novartis was also granted
“orphan drug” status for Kymriah.
58
Novartis received market approval for Kymriah in the EU on
August 27, 2018.
59
This approval authorizes the marketing of Kymriah
in the EU for two indications: the treatment of B cell ALL that is
refractory, in relapse post-transplant or in second or later relapse in
patients up to 25 years of age; and the treatment of relapsed or
52. Id.
53. Id.
54. Id.
55. NOVARTISAPPROVAL LETTER, supra note 3, at 1.
56. Id.
57. Id. at 4.
58. Id. at 5. Orphan drug designation in the United States is designed to
encourage sponsors to develop products intended for rare diseases or conditions (i.e.,
conditions that affect fewer than 200,000 individuals in the United States or that
affect more than 200,000 individuals in the United States and for which there is no
reasonable expectation that the cost of developing and making available the product
will be recovered from U.S. sales of the product). An orphan drug designation
granted by the FDA confers on the sponsor a seven-year market exclusivity. An
application for designation as an orphan product can be made any time prior to the
filing of an application for approval to market a product. See Developing Orphan
Products: FDA and Rare Disease Day, FDA (2011), https://www.fda.gov/
forindustry/Developingproductsforrarediseasesconditions/ucm239698.htm.
59. Summary of European Union Decisions on Marketing Authorization in
Respect of Medicinal Products from 1 August 2018 to 31 August 2018, 2018 O.J.
(C 349) 1, 2 (EC).
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refractory diffuse large B cell lymphoma (DLBCL) after two or more
lines of systemic therapy in adult patients.
60
Kymriah also received
orphan market exclusivity in Europe.
61
Novartis obtained approval for Kymriah in Canada on September 5,
2018.
62
The authorization by Health Canada covers the following
indication: treatment of pediatric and young adult patients 3 to 25
years with B-cell ALL who are refractory, have relapsed after
allogeneic stem cell transplant (SCT) or are otherwise ineligible for
SCT, or have experienced second or later relapse.
63
Kite Pharma received U.S. market approval history for Yescarta
(axicabtagene ciloleucel) on October 18, 2017.
64
This approval
authorizes Yescarta “for the treatment of adult patients with relapsed
or refractory large B-cell lymphoma after two or more lines of
systemic therapy, including diffuse large B-cell lymphoma (DLBCL)
not otherwise specified, primary mediastinal large B-cell lymphoma,
high grade B-cell lymphoma, and DLBCL arising from follicular
60. See Product Information (Kymriah), EUR. COMM’N: PUBLIC HEALTH,
http://ec.europa.eu/health/documents/community-register/html/h1297.htm. (last
visited Feb. 18, 2019) (explaining the parameters for authorized marketing of
Kymriah).
61. See id. EC Regulations No. 141/2000 and No. 847/2000 provide that a
product can be designated as an orphan drug by the European Commission if its
sponsor can establish that the product is intended for the diagnosis, prevention, or
treatment of (i) a life-threatening or chronically debilitating condition affecting not
more than five in ten thousand persons in the EU, or (ii) a life-threatening, seriously
debilitating, or serious and chronic condition in the EU that, without additional
incentives, is unlikely to generate sufficient returns to justify the investment
necessary to produce and market the product. In each of these cases, the applicant
must demonstrate that no authorized method of diagnosis, prevention, or treatment
of the condition in question exists or, if such method exists, the product will be of
significant benefit to those affected by the relevant condition. Marketing
authorization for an orphan drug confers a ten-year period of market exclusivity
(which may be reduced to six years if, at the end of the fifth year, the product no
longer meets the criteria for orphan drug designation). See Council Regulation
141/2000, 2000 O.J. (L 18) 1, 4–5 (EC); Commission Regulation 847/2000, 2000
O.J. (L 103) 1, 5 (EC).
62. Regulatory Decision Summary – Kymriah – Health Canada, GOV. CAN.:
HEALTH PRODUCT REG., https://hpr-rps.hres.ca/reg-content/regulatory-decision-
summary-detail.php?linkID=RDS00423 (last visited Feb. 18, 2019).
63. Id.
64. See KITEAPPROVAL LETTER, supra note 4.
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lymphoma.”
65
Kite Pharma received market approval for Yescarta in the EU on
August 27, 2018.
66
This approval grants Yescarta an orphan market
exclusivity that is due to expire on August 27, 2028.
67
In the EU
Yescarta is indicated for the treatment of adult patients with relapsed
or refractory diffuse large B-cell lymphoma (DLBCL) and primary
mediastinal large B-cell lymphoma (PMBCL), after two or more lines
of systemic therapy.
68
Most recently, CRISPR Therapeutics has received FDA approval
for an investigational new drug application for its CTX001 CAR-T
therapy targeting beta thalassemia and sickle cell disease.
69
Beyond this, many more CAR-T and other gene and cell therapy are
likely to seek regulatory approval in the near future. One commentator
reports that in February 2019, there were nearly 700 CAR-T studies
registered in the NIH’s ClinicalTrials.gov database.
70
C. THE PATENTING OFCAR-T
As with many new biomedical developments, the firms bringing
CAR-T treatments to market have acquired patents covering many
aspects of these treatments. One of the first U.S. patents covering
CAR-T technology is entitled “Nucleic Acids Encoding Chimeric T
Cell Receptors” and was issued in 2008 to the Sloan-Kettering
Institute for Cancer Research in New York.
71
The thirteen claims of
this patent (one independent and twelve dependent) claim various
configurations of a “nucleic acid polymer encoding a chimeric T cell
65. Id.
66. Summary of European Union Decisions on Marketing Authorization in
Respect of Medicinal Products from 1 August 2018 to 31 August 2018, supra note
59, at 2.
67. Product Information (Yescarta), EUR. COMM’N: PUB. HEALTH,
http://ec.europa.eu/health/documents/community-register/html/h1299.htm#
EndOfPage (last visited Feb. 18, 2019).
68. Id.
69. Bailey Lipschultz, Crispr Got FDA Nod for Another Gene Editing Study,
Dosing Next, BLOOMBERG LAWNEWS, Apr. 29, 2019.
70. Baumann, supra note 9.
71. SeeU.S. Patent No. 7,446,190 B2 (filedMay 28, 2003) (issued Nov. 4, 2008)
(featuring the full patent for Nucleic Acids Encoding Chimeric T Cell Receptors).
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receptor”—a composition of matter.
72
This patent, in turn, has been
cited by ninety-seven later patents and patent applications.
73
As
discussed below, many of these later patents and applications claim
not only compositions of matter, but methods of treating various
diseases using CAR-T technologies.
In April 2019, Björn Jürgens and Nigel Clarke published a study of
CAR-T patenting commissioned by the European Patent Office
(EPO).
74
Jürgens and Clarke report that the patenting of CAR-T
inventions began in earnest in 2013 with sixty filings around the world
and increased through 2016 to 597 filings.
75
Of a total of 1,914 patent
documents filed between 2013 and 2016, the greatest number were
filed by applicants originating in the U.S. (39%) and China (33%),
followed by the UK (5%), Germany (5%), Japan (4%) and France
(3%).
76
The jurisdictions in which patent documents were filed
included the U.S. (373 documents), the EPC (183 documents),
Australia (146 documents), and Canada (127 documents).
77
The authors conducted a further analysis of CAR-T patent filings.
Table 1 shows the results of a search in the USPTO patent database
for issued patents and published patent applications containing the
term “chimeric antigen receptor” either in all of the search fields, in
their abstracts, or in their claims.
78
72. Id. (“This application relates to nucleic acid polymers encoding chimeric T
cell receptors. . . .”).
73. See Nucleic Acids Encoding Chimeric T Cell Receptors, GOOGLE PATENTS,
https://patents.google.com/patent/US7446190B2/en?oq=7%2c446%2c190 (search
“Pat. No. 7,446,190” then scroll down to “cited by”) (last visited Feb. 18, 2019)
(providing a list of all publications that have cited to Pat. No. 7,446,190).
74. Björn Jürgens & Nigel Clarke, Evolution of CAR T-cell immunotherapy in
terms of patenting activity, 37 NATURE BIOTECHNOLOGY 370 (2019).
75. Id. at 371.
76. Id. at 372.
77. Id. and supplemental information provided to the authors by Nigel Clarke
via email on May 20, 2019 (copy on file with the authors).
78. See Chimeric Antigen Receptor, U.S. PAT. AND TRADEMARK OFF.,
http://patft.uspto.gov/netahtml/PTO/search-bool.html (search “Chimeric Antigen
Receptor” then adjust dates) (last visited Feb. 20, 2019); see also Chimeric Antigen
Receptor, U.S. PAT. AND TRADEMARK OFF., http://appft.uspto.gov/netahtml/PTO/
search-bool.html (search “Chimeric Antigen Receptor”) (last visited Feb. 20, 2019).
This search strategy is consistent with that of Jürgens & Clarke, supra note 74, at
Supp.
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Table 1 – U.S. issued patents and patent applications citing “chimeric
antigen receptor”, by year
79
Issued patents Published applications
Year
All fields Abstract Claims All fields Abstract Claims
2011
0 0 0 6 0 0
2012
0 0 0 12 1 7
2013
4 0 2 32 3 15
2014
10 1 6 65 20 38
2015
27 1 12 104 14 45
2016
64 8 24 239 35 123
2017
117 15 41 455 67 200
2018
195 14 57 730 103 327
Table 1 is not intended to be a comprehensive landscape of CAR-T
patenting activity in the U.S.
80
Although the fact that a patent
document mentions the phrase “chimeric antigen receptor” in the
description or any other field is indicative, this does not necessarily
mean that it is claiming a CAR-T therapy. Conversely, CAR-T
therapies may be claimed in patent documents without using the
phrase “chimeric antigen receptor,” and such patent documents are not
included in the search strategy described in Table 1. For instance, as
of March 2019, there are three issued patents in the U.S. that use the
phrase “synthetic T-cells” but do not mention the phrase “chimeric
antigen receptor”; similarly, there is one issued patent in the U.S.
citing “CAR-modified T-cells” that does not mention “chimeric
antigen receptor.” Nevertheless, Table 1 provides an easily-replicable
illustration of the growth in patents and applications mentioning
79. Id.
80. For patent landscaping guidelines in the life sciences, see e.g., Tania Bubela,
E Richard Gold, Gregory D Graff, Daniel R Cahoy, Dianne Nicol and David Castle,
Patent landscaping for life sciences innovation: toward consistent and transparent
practices, 31 NATURE BIOTECHNOLOGY 202 (2013); Mateo Aboy, Kathy Liddell,
Johnathon Liddicoat, and Cristina Crespo, Myriad’s Impact on Gene Patents, 34
NATURE BIOTECHNOLOGY 1119 (2016).
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“chimeric antigen receptor.”
In Europe, the number of CAR-T patents appears to be lower. An
Espacenet search for B1, B2, or B3 documents (codes used to identify
granted patents) citing the phrase “chimeric antigen receptor” in the
title or abstract only returns nine European patents.
81
Two of those
patents claimed methods where one of the steps involves
administering T cells to a patient.
82
A PatentScope search
83
for applications that include any of the
following phrases: “administering to a patient,” “administering to a
subject,” “administering to said subject,” and “administering to said
patient,” conducted in October 2018, returned a total of eighty-three
patent applications filed at the EPO. A review of these eighty-three
applications using the European Patent Register online legal status
database
84
reflects that as of December 2018, seventy-five of those
applications were still pending,
85
and six have been withdrawn. The
EPO has expressed its intent to grant only two of those eighty-three
applications; in both of those applications the claims with the term
“administering [. . .]” were abandoned, eliminated during
examination, or were not introduced at the EPO despite being present
in the priority application.
86
These figures are lower than those
reported by Jürgens & Clarke, most likely due to the more restrictive
search terms that we employed.
81. See Espacenet Patent Search, EUR. PAT. OFF.,
https://worldwide.espacenet.com (last visited Feb. 16, 2019) (listing all patents
within this search, including those from countries outside of Europe).
82. See id.
83. SeeWORD INTELL. PROP. ORG.: PATENTSCOPE, https://patentscope.wipo.int/
search/en/search.jsf (last visited Feb. 16, 2019) (providing the complete results of
the aforementioned search).
84. European Patent Register, EUR. PAT. OFF., https://register.epo.org/
regviewer (last visited Feb. 16, 2019).
85. Id. In the context of this paper pending means that a published application
has not yet been issued, rejected, or withdrawn. At the European Patent Register
database, the legal status of pending applications could be coded in several ways,
including as “the application has been published”, “request for examination was
made”, “examination is in progress.”
86. Id.
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II. PATENT EXCLUSIONS FOR METHODS OF
MEDICAL TREATMENT
A. BACKGROUND: NINETEENTH AND EARLY TWENTIETH
CENTURIES
Since the early days of patenting there has been unease with regard
to granting particular inventors exclusive rights over methods of
medical treatment. Objections to the patenting of medical treatments
have their roots in basic moral principles—it is wrong to limit the
availability of potential lifesaving treatments to individuals in need—
as well as ethical precepts of the medical profession.
87
That is, in
keeping with the Hippocratic Oath, it was argued that “in order to
ensure the best possible health treatment, physicians must always be
free in their choice of treatment.”
88
Thus, when the American Medical
Association adopted its first Code of Ethics in 1847, its members
agreed that obtaining a patent on a medical procedure was “derogatory
to professional character.”
89
Patent offices and courts around the world generally agreed with the
assessment of the medical community and effectively prohibited
patents on methods of medical treatment through the nineteenth and
early twentieth centuries.
90
Accordingly, patents were denied or
87. Oksana Mitnovetski & Dianne Nicol, Are Patents for Methods of Medical
Treatment Contrary to the Ordre Public and Morality or “Generally
Inconvenient”?, 30 J.MED. ETHICS 470, 470 (2004) (“Medical law has its origins in
the Hippocratic Oath, and the goal is the preservation of human life. Since the goal
of patent law is to encourage innovation by rewarding inventors, it is quite distinct
from the goal of medical law.”).
88. Id.
89. See Katherine J. Strandburg, Derogatory to Professional Character? The
Evolution of Physician Anti-Patenting Norms, in CREATIVITY WITHOUT LAW:
CHALLENGING THEASSUMPTIONSOF INTELLECTUALPROPERTY63, 63 (Kate Darling
& Aaron Perzanowski, eds., 2017) [hereinafter Strandburg, Derogatory to
Professional Character?]; see also Katherine J. Strandburg, Legal But
Unacceptable: Pallin v. Singer and Physician Patenting Norms, in INTELLECTUAL
PROPERTY AT THE EDGE 321, 323 (Rochelle Dreyfuss & Jane Ginsburg eds., 2014)
[hereinafter Strandburg, Legal But Unacceptable] (noting that the AMA’s medical
first Code of Ethics in 1847 found it to be unethical for a physician to hold a patent).
In the early years of the twentieth century, a similar aversion to the patenting of
drugs can be found. See JOSEPHGABRIEL, MEDICALMONOPOLY (2014).
90. See Strandburg, Legal but Unacceptable, supra note 89, at 321–23 (outlining
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invalidated in the United States for the use of ether as a surgical
anesthetic
91
and for the treatment of skin infections using light rays.
92
Patents were also denied in the United Kingdom for a process for
extracting toxic lead from a patient,
93
and in Germany for the
therapeutic administration of oxygen through a hydrogen peroxide
bath.
94
In many of these cases, particularly in Europe, courts reasoned
that a patent could not be issued for a process that failed to result in a
“vendible product”—something that could be sold.
95
France and Italy
adopted a test of “industrial character” for the issuance of patents on
medical innovations,
96
and Austria and Switzerland based the refusal
of such patents on ethical grounds.
97
Yet despite these early inclinations against patenting medical
treatments, the tide began to shift during the 1950s. One watershed
occurred in 1954, when the U.S. Patent and Trademark Office
expressly overturned an 1883 decision prohibiting the patenting of
the early history of the medical community’s attitude towards medical patents); see
also Mitnovetski & Nicol, supra note 87, at 471–72 (tracing the history in the UK
and Europe of excluding medical treatments from patenting).
91. Morton v. New York Eye Infirmary, 17 F. Cas. 879, 884 (C.C.S.D.N.Y.
1862) (No. 9865); see Strandburg, Derogatory to Professional Character?, supra
note 89, at 64–74 (describing the ether patenting controversy).
92. See Ex Parte Brinkerhoff, 24 Dec. Comm’r 349 (1883), reprinted in New
Decisions, 27 J. PAT. & TRADEMARK OFF. SOC’Y 793, 798 (1945) (discussing a
patent on “treating animal tissues by subjecting the same to the action of light rays
lying within a certain region of the spectrum, the tissues being shielded from wave
lengths lying within other regions of the spectrum”).
93. In the Matter of C. & W.’s Application for a Patent, 31 RPC 235, 235–36
(1914).
94. Badewasser Patent, Dec. 30, 1904, Blatt für Patent-, Muster- und
Zeichenwesen [BlfPMZ], vol. 11, no. 1, at 4–5 (Jan. 25, 1905) (Ger.),
https://babel.hathitrust.org/cgi/pt?id=mdp.35112104213360;view=1up;seq=25. But
see Reiner Moufang,Methods of Medical Treatment Under Patent Law, 24 INTERN.
REV. IND. PROP. & COPYRIGHT L. 18, 22 note 13 (1993) (listing a handful of early
German patents issued on medical methods, but never challenged in court, e.g.,
German patent No. 150666 (1903) for a method of removing stitches from wounds,
and German patent No. 150699 (1903) for treating human spinal curvature).
95. Mitnovetski & Nicol, supra note 87, at 471 (“[I]t [has been] accepted as
axiomatic that there [can] be no patents for medical treatment, because they do not
result in . . . a product that can be sold.”).
96. Id.
97. Id.
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medical procedures.
98
In 1959 the Australian High Court ruled that a
method need not result in a “vendible product” in order to be
patentable, expressly departing from the earlier rule expressed in the
UK.
99
These events, and the increase in patenting activity that
followed, contributed to renewed interest in medical treatment patents
around the world.
B. THEMETHODS OF TREATMENT EXCLUSIONUNDER THE
EUROPEAN PATENT CONVENTION
The European Patent Convention (EPC) is a multilateral treaty
among thirty-eight European signatory states representing both
members and non-members of the European Union.
100
It establishes a
system whereby patent applications may be filed and examined for
patentability by a common agency, the European Patent Office (EPO)
based in Munich, and then issued as national patents in each of the
signatory states (subject to translation and other procedural
requirements).
101
Negotiations and planning for the EPC began as early as 1949 and,
in various fits and starts, evolved through numerous stages.
102
By
98. SeeEx parte Scherer, 103 U.S.P.Q (BNA) 107, 110 (Pat. Off. Bd. App. 1954)
(stating, in regards toMorton, “[i]t is believed that no proper inference that any and
all medical or surgical methods are excluded from the field of patentable subject
matter can be drawn from the opinion, and neither do the facts upon which the
opinion is based warrant such a broad generalization.”); see also Strandburg,
Derogatory to Professional Character?, supra note 89, at 76; William D. Noonan,
Patenting Medical and Surgical Procedures, 77 J. PAT. & TRADEMARKOFF. SOC’Y
651, 655 (1995) (noting that, in 1948, the American Medical Association Judicial
Council issued an Official Opinion stating that is no longer considered medical
patents to be necessarily unethical).
99. See Nat’l Research Dev. Corp. v. Comm’r of Patents, (1959) 102 CLR 252,
253 (Austl.) (holding that the product was patentable because “it consist[ed] in an
artificially created state of affairs . . . [a]nd the significance of the product is
economic; for it provides a remarkable advantage”); see alsoMitnovetski & Nicol,
supra note 87, at 471.
100. Convention on the Grant of European Patents, Oct. 5, 1973, 1065 U.N.T.S.
199 (entered into force Oct. 7, 1977), as amended by the Act revising the Convention
on the Grant of European Patents of Nov. 29, 2000 (entered into force Dec. 13, 2007)
[hereinafter EPC].
101. See id. (explaining the process and requirements for obtaining a patent in
Europe).
102. See SIGRID STERCKX & JULIAN COCKBAIN, EXCLUSIONS FROM
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1969, a first draft of the EPC was developed which listed numerous
exclusions from patentability, including “methods of treatments,
including methods of diagnosis.”
103
There was debate throughout the negotiation of the EPC whether
this exclusion from patentability was based on the notion that patents
on medical treatments were contrary to ordre public and morality
104
or
because, as argued by the German delegation, such patents were not
“susceptible of industrial application”
105
(i.e., harkening back to the
UK’s original assessment of such patents as failing to result in
vendible products). By the signing of the EPC in 1973, the German
view prevailed, and Article 52[4] provided that:
Methods for treatment of the human or animal body by surgery or therapy
and diagnostic methods practised on the human or animal body shall not be
regarded as inventions which are susceptible of industrial application . . .
This provision shall not apply to products, in particular substances or
compositions, for use in any of these methods.
106
The EPC entered into effect in July 1978, and the signatory states
soon amended their national patent laws to conform to its
PATENTABILITY: HOW FAR HAS THE EUROPEAN PATENT OFFICE ERODED
BOUNDARIES? 21–39 (Cambridge Univ. Press ed. 2012) (outlining the historical
development of the EPC).
103. EPC, First Preliminary Draft of a Convention Establishing a European
System for the Grant of Patents, art. 9(2)(e) (1970) [hereinafter EPC, First
Preliminary Draft of a Convention Establishing a European System for the Grant of
Patents]. The debates over the EPC were extensive and lengthy. In terms of
exclusions from patentability, topics such as the patentability of computer programs,
mental processes, and mathematical formulae were particularly contentious. See
STERCKX&COCKBAIN, supra note 102, at 40–45.
104. See STERCKX & COCKBAIN, supra note 102, at 23 (quoting Roger Gajac’s
1955 study on substantive points of patentability; see also Mitnovetski & Nicol,
supra note 87, at 470, 472 (explaining that the concept of ordre public “expresses
concerns about matters threatening the social structures which tie a society
together”). Among the technologies expressly viewed as contrary to the ordre public
by the EPO are anti-personnel mines. See STERCKX & COCKBAIN, supra note 102,
at 57 (providing that at EPC 1973, attendees were told that the EPO believed that
inventions “relating to anti-personnel mines per se should be excluded from
patentability as contrary to ‘ordre public’ and morality”).
105. See STERCKX & COCKBAIN, supra note 102, at 46–47 (asserting that the
German view that medical methods are not susceptible of industrial application is a
“legal fiction”).
106. EPC art. 52(4), supra note 100.
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requirements.
107
Not all countries, however, adopted the “industrial
application” language justifying the exclusion of medical treatments
from patentability. Denmark, Italy, and Sweden, for example, treated
medical treatments as non-inventions, and Switzerland simply
characterized them as legal exceptions to patentable subject matter.
108
Dissatisfaction with the EPC arose soon after its adoption, and
negotiations began for its amendment.
109
These negotiations were
influenced,
110
among other things, by the negotiation and ratification
of the TRIPS Agreement as part of the World Trade Organization
Treaty in 1994
111
and the adoption by the EU of the European
Biotechnology Directive of 1998.
112
As part of this debate, the
“fiction” that certain technologies such as medical treatments lacked
industrial application came under fire, largely as part of the larger
debate over the patentability of computer software.
113
As a result, in the major amendments to the EPC adopted in 2000,
which came into force in 2007, the exclusion for medical treatments
was moved from Article 52, which permitted patents to be granted on
all inventions “susceptible of industrial application,” to Article 53,
which included exceptions for inventions “the commercial
exploitation of which would be contrary to ‘ordre public’ or
morality.”
114
In this manner, the idea that medical treatments lacked
industrial application was dispensed with, and it was accepted that the
medical treatment exclusion was intended to serve “the interests of
107. Mitnovetski & Nicol, supra note 87, at 471–72 (“Shortly after signing the
EPC, the member states began adjusting their legal systems to accord with European
uniform law, and article 52(4) was largely adopted.”).
108. Id. at 471.
109. See STERCKX & COCKBAIN, supra note 102, at 49–65 (tracing the
amendments to the EPC, which were born out of dissatisfaction with the original
convention).
110. See id. at 50–59.
111. Agreement on Trade-Related Aspects of Intellectual Property Rights,
Including Trade in Counterfeit Goods, Apr. 15, 1994, 1869 U.N.T.S. 299, 33 I.L.M.
881 [hereinafter TRIPS Agreement]. See discussion infra Part II.B (discussing the
medical treatments exclusion under TRIPS).
112. Council Directive 98/44/EC, 1998 O.J. (L 213) 13 (EC).
113. See STERCKX & COCKBAIN, supra note 102, at 62–65 (outlining various
delegations that criticized this idea).
114. See id. at 64–66. These amendments were, in part, enacted to bring the EPC
into compliance with the TRIPS Agreement.
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public health.”
115
The final text of the EPC exclusion for medical
treatments, as it exists today, thus reads:
Article 53 – Exceptions to Patentability
European patents shall not be granted in respect of . . . methods for
treatment of the human or animal body by surgery or therapy and diagnostic
methods practised on the human or animal body; this provision shall not
apply to products, in particular substances or compositions, for use in any
of these methods.
116
The EPO Boards of Appeal have subsequently confirmed that the
exclusion of methods of medical treatment from patentability is
“based on social-ethical and public health considerations”
117
and that
“physicians should be free to choose the best medical treatment for a
patient without being prevented by exclusive patent rights.”
118
Likewise courts in Europe have confirmed this focus, holding that
“patent law should not interfere with the saving of human life or the
alleviation of human suffering.”
119
C. METHODS OF TREATMENTUNDER TRIPS ANDOTHER
INTERNATIONAL TRADE AGREEMENTS
As discussed above, the EPC establishes certain requirements
regarding patent eligibility among its signatory states. Among these is
115. See id. at 62–63.
116. EPC art. 53(c), supra note 100.
117. See Decision G 0002/08, 2010 O.J. Eur. Pat. Off. 1; Decision T 0024/91-
3.2.02, 1994 O.J. Eur. Pat. Off. 1; STERCKX & COCKBAIN, supra note 102, at 157
(“[T]he exclusion of methods of medical treatment has been on societal and ethical
grounds rather than on the basis that such methods could not be ‘inventions.’”);
Stefan Bechtold, Physicians as User Innovators in INTELLECTUALPROPERTY AT THE
EDGE (Rochelle Dreyfuss & Jane Ginsburg eds., 2014) (“It is now widely accepted
that the exception of Article 53(c) EPC is primarily driven by ethical, moral, and
public health concerns.”).
118. Bechtold, supra note 117(citing European Patent Office, Tech. Bd. App.,
University of Manitoba/Lung ventilator device (T 0592/98), at ¶ 2 (2001),
http://www.epo.org/law-practice/case-law-appeals/advanced-search.html; Enl. Bd.
App., Cygnus/Diagnostic methods (G 1/04), [2006] E.P.O.R. 15, 161, 171; Enl. Bd.
App., Medi-Physics/Treatment by surgery (G 1/07), [2010] E.P.O.R. 25, 225, 227;
Tech. Bd. App., Wellcome/Pigs 1 (T 116/85), [1988] E.P.O.R. 1, 5).
119. Bechtold, supra note 117 (citing, inter alia, Wellcome Foundation Ltd. v.
Plantex, [1979] RPC 514, 540 (Eng.)).
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the Article 53(c) exclusion of patentability for medical treatments.
120
This approach differs from that taken by the TRIPS Agreement.
Negotiations for the Uruguay round of the General Agreement on
Tariffs and Trade (GATT) began in September 1986.
121
The treatment
of intellectual property rights was always an important part of these
negotiations, and in 1988 a basic framework for the treatment of
intellectual property was agreed among the United States, the EU and
Japan.
122
The TRIPS Agreement, which was signed in in 1994 and
went into effect in 1995, requires that signatory states provide
minimum requirements for patentability, such as a 20-year term, non-
discrimination among subject areas, national treatment for foreign
applications, and the like.
123
In addition, the TRIPS Agreement
permits, but does not require, the exclusion of certain categories of
inventions from patent protection.
124
In particular, TRIPS Article
27(3) provides that signatories may, if they so choose, exclude from
patentability “diagnostic, therapeutic and surgical methods for the
treatment of humans or animals.”
125
The TRIPS approach to excluding patentability of medical
treatments has been followed in numerous other multilateral and
bilateral treaties, a representative list of which is included in Appendix
A.
126
Several trade agreements provide this flexibility simply by
referencing Article 27(3) of the TRIPS Agreement,
127
whereas others,
120. EPC art. 53(c), supra note 100.
121. Michael D. Wilkinson, Lobbying for Fair Trade: Northern NGDOS, the
European Community and the GATT Uruguay Round, 17 THIRDWORLDQ. 251, 251
(1996).
122. STERCKX&COCKBAIN, supra note 102, at 50.
123. TRIPS Agreement art. 33, supra note 111.
124. Allowing, but not requiring, certain features to be incorporated into national
law by signatory states is known as a treaty “flexibility.” See, e.g., TRIPS Agreement
art. 27(2)-(3), supra note 111 (offering several such flexibilities to its signatories);
Laurence R. Helfer, Flexibility in International Agreements, in INTERDISCIPLINARY
PERSPECTIVES ON INTERNATIONAL LAW AND INTERNATIONAL RELATIONS 175, 175
(Jeffrey L. Dunoff & Mark A. Pollack eds., 2013) (“These [treaty flexibility]
provisions function as insurance policies. They provide a hedge against uncertainty
that allows a state to revise, readjust, or even renounce its commitments if the
anticipated benefits of treaty-based cooperation turn out to be overblown.”).
125. TRIPS Agreement art. 27(3), supra note 111.
126. See discussion infra Appendix A.
127. See, e.g., Trade Promotion Agreement, Colom.-U.S., art. 16.9, Nov. 22,
2006, https://ustr.gov/trade-agreements/free-trade-agreements/colombia-fta/final-
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such as the Trans-Pacific Partnership (TPP) Agreement, enumerate
this exception expressly.
128
As noted above, the adoption of the medical treatment exclusion
under TRIPS Article 27(3) influenced the negotiation of the EPC and
its 2000 amendments.
129
It also had a notable impact on the national
laws of many other countries outside of Europe. A recent review of
national laws reveals that more than sixty countries including China,
Japan, and India have implemented some form of statutory
patentability exclusion for medical treatments.
130
D. METHODS OF TREATMENT IN THEUNITED STATES: STATUTORY
IMMUNITY AND PATENTABLE SUBJECTMATTER
The handling of medical treatment patents in the United States is
somewhat unique and does not follow the TRIPS model outlined
above.
131
As noted in Part II.A, the U.S. Patent and Trademark Office
text (entered into force May 15, 2012); Agreement, Peru-U.S., art. 16.9, Apr. 12,
2006, https://ustr.gov/sites/default/files/uploads/Countries%20Regions/africa/
agreements/pdfs/FTAs/peru/16%20IPR%20Legal.June%2007.pdf (“Nothing in this
Chapter shall be construed to prevent a Party from excluding inventions from
patentability as set out in Articles 27.2 and 27.3 of the TRIPS Agreement.”).
128. Trans-Pacific Partnership Agreement, art. 18.37, para. 3 (“A Party may also
exclude from patentability: (a) diagnostic, therapeutic and surgical methods for the
treatment of humans or animals.”). See Comprehensive and Progressive Agreement
for Trans-Pacific Partnership art. 18.7, Feb. 4, 2016, https://www.mfat.govt.nz/
assets/Trans-Pacific-Partnership/Text/18.-Intellectual-Property-Chapter.pdf
(incorporating by reference all but 22 of the original TPP provisions, signed by the
TPP countries except the United States, incorporated by reference paragraph 3 of
TPP article 18.37).
129. EPC art. 53(c), supra note 100.
130. Luis Abinader, Review of National Laws Implementing Statutory
Patentability Exclusions for Medical Treatments (Oct. 2018) (unpublished study)
(on file with author). See list infra App. B (providing a complete list of these
countries).
131. In fact, some U.S. industry organizations have objected to the
implementation of TRIPS flexibilities in this area by other countries. See, e.g.,
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
SPECIAL 301 SUBMISSION 2018 87 (2018), https://www.phrma.org/policy-
paper/phrma-special-301-submission-2018 [hereinafter PHRMA] (arguing that
India should be included on a U.S. Department of State list of countries abusing
intellectual property laws because “Section 3(i) of the Indian Patents Act excludes
method of treatment claims preventing U.S. biotechnology companies with needed
treatment methods from entering the Indian market and providing life-saving
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began to allow patents on medical treatment methods in 1954.
132
Yet
few physicians availed themselves of this right or enforced their
patents for several decades. This situation changed in the early 1990s,
when ophthalmological surgeon Dr. Samuel Pallin applied for and
received a patent covering a method of sutureless cataract surgery.
133
Shortly thereafter, as Professor Katherine Strandburg describes, Pallin
began to assert the patent and seek royalties from other eye surgeons
including Dr. Jack Singer.
134
Singer refused to acquiesce to Pallin’s
royalty demands and instead marshalled the medical community to
oppose not only Singer’s patent, but all patents covering medical and
surgical techniques.
135
The debate soon reached a national scale and
the American Medical Association issued a report in 1995 concluding
that it is unethical for physicians to “seek, secure or enforce patents on
medical procedures.”
136
Despite significant counter-lobbying by the
biotechnology industry,
137
in 1996 Congress added Section 287(c) to
the Patent Act to deal with medical treatment patents.
138
Unlike national statutory schemes that take advantage of the
exclusionary flexibilities under TRIPS, Section 287(c) does not
prohibit the patenting of medical treatments outright.
139
Instead, it
creates a limited immunity from patent infringement for medical
practitioners and related healthcare entities who practice a patented
products”).
132. See discussion supra Part II.A.
133. U.S. Patent No. 5,080,111 (filed June 28, 1990); see Strandburg, Derogatory
to Professional Character?, supra note 89, at 328–29 (discussing Pallin’s patent and
motivations for seeking it).
134. Pallin v. Singer, No. 2:93-CV-202, 1996 WL 274407 (D. Vt. Mar. 28, 1996)
(finding that Pallin’s patent was invalid and not infringed); see Strandburg,
Derogatory to Professional Character?, supra note 89, at 63, 77 (discussing Pallin’s
case against Singer).
135. See Strandburg, Derogatory to Professional Character?, supra note 89, at
63, 77 (discussing medical community opposition to medical treatment patents).
136. Proceeding of the House of Delegates, 144 AM. MED. ASS’N 1, 206 (1995),
http://www.ama-assn.org/ama/pub/about-ama/our-history/ama-historicalarchives/
the-digital-collection-historical-ama-documents.page.
137. See Strandburg, Derogatory to Professional Character?, supra note 89, at
63, 77; see also Bradley J. Meier, New Patent Infringement Liability Exception for
Medical Procedures, 23 J. LEGIS. 265, 265 (2015).
138. Pub. L. No. 104-208, § 616, 110 Stat. 3009 (1996) (codified as amended at
35 U.S.C. § 287(c)).
139. TRIPS Agreement art. 27(2)-(3), supra note 111.
2019] PATENTABILITY OFGENETIC THERAPIES 731
“medical activity.”
140
There are numerous exclusions from this
immunity, including the use of a patented machine or composition of
matter, the practice of a patented use of a machine or composition of
matter, the practice of a process in violation of a “biotechnology
patent,”
141
and the activity of any person engaged in commercial
development of a machine or composition of matter.
142
Thus, while the
U.S. approach shields physicians, hospitals, and clinics from liability
for performing patented surgical, medical, and diagnostic procedures,
it does not inhibit the enforcement of patents covering medical devices
or drugs or against commercial interests.
143
Despite the immunity granted under Section 287(c), physicians,
biopharmaceutical companies, and medical device manufacturers in
the United States continued to obtain patents covering medical
treatments in significant numbers.
144
But in 2012, the Supreme Court
cast doubt on the patentability of certain medical procedures,
particularly diagnostic methods, under Section 101 of the Patent Act.
InMayo Collaborative Services v. Prometheus,
145
the Court evaluated
a patent that claimed a “method of optimizing therapeutic efficacy for
treatment of an immune-mediated gastrointestinal disorder.”
146
In
creating its now well-known two-part test for patent eligibility, the
Court asked first whether the patent claim in question recited a law of
nature and, if so, whether the claim added enough to qualify as an
application of that natural law.
147
With respect to Prometheus’s claims,
140. A “medical activity” is defined as “the performance of a medical or surgical
procedure on a body.” 35 U.S.C.S. § 287(c)(2)(A) (LEXIS through Pub. L. No. 115-
391).
141. Id.
142. Id. § 287(c)(3).
143. At least one commentator has argued that the U.S. immunity under Section
287(c) violates the TRIPS Agreement. See Emily C. Melvin, Note, An Unacceptable
Exception: The Ramifications of Physician Immunity from Medical Procedure
Patent Infringement Liability, 91 MINN. L. REV. 1088, 1089–90 (2007).
144. See, e.g., Aaron K. Chatterji et al., Physician-Industry Cooperation in the
Medical Device Industry, 27 HEALTHAFF. 1532, 1535, 1537–38 (2008) (estimating
that approximately 20% of medical device patents have at least one physician
inventor).
145. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 90
(2012).
146. Id. at 74.
147. Id.
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the Court held that they merely involved well-understood, routine,
conventional activity previously engaged in by researchers in the field,
and thus failed to meet the threshold for patentability.
148
Much has been made of the uncertainty surrounding Section 101
patent eligibility that resulted from the Supreme Court’s holding in
Mayo and its 2014 decision in Alice v. CLS Bank.
149
A number of U.S.
courts have invalidated medical treatment patents under Section 101
after applying the two-step test established in Mayo. For example, in
Mallinckrodt Hospital Prods. IP Ltd. v. Praxair Distrib., Inc.,
150
the
court considered the following patent claim:
1. A method of treating patients who are candidates for inhaled nitric oxide
treatment, which method reduces the risk that inhalation of nitric oxide gas
will induce an increase in pulmonary capillary wedge pressure (PCWP)
leading to pulmonary edema in neonatal patients with hypoxic respiratory
failure, the method comprising:
(a) identifying a plurality of term or near-term neonatal patients
who have hypoxic respiratory failure and are candidates for 20
ppm inhaled nitric oxide treatment;
(b) determining that a first patient of the plurality does not have
left ventricular dysfunction;
(c) determining that a second patient of the plurality has left
ventricular dysfunction, so is at particular risk of increased
PCWP leading to pulmonary edema upon treatment with
inhaled nitric oxide;
(d) administering 20 ppm inhaled nitric oxide treatment to the
first patient; and
148. Id. at 77–80.
149. See Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208, 212 (2014)
(holding that a computer program for facilitating complex international financial
transactions is an abstract idea that cannot be patented). For critiques of these
decisions, see, e.g., Kevin Madigan &AdamMossoff, Turning Gold into Lead: How
Patent Eligibility Doctrine is Undermining U.S. Leadership in Innovation, 24 GEO.
MASON L. REV. 939, 950–52 (2017); Dan L. Burk, Dolly and Alice, 3 J. L. &
BIOSCIENCES 606, 609–11 (2015).
150. Mallinckrodt Hosp. Prods. IP Ltd. v. Praxair Distribution, Inc., Civil Action
No. 15-170-GMS, 2017 U.S. Dist. LEXIS 142644, at *19 (D. Del. Sept. 5, 2017).
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(e) excluding the second patient from treatment with inhaled
nitric oxide, based on the determination that the second patient
has left ventricular dysfunction, so is at particular risk of
increased PCWP leading to pulmonary edema upon treatment
with inhaled nitric oxide.
151
The court found this claim to be patent ineligible under Section 101
on the basis that the “core” of the alleged invention, treatment of
hypoxic respiratory failure with inhaled nitric oxide, was a patent
ineligible law of nature.
152
And as to whether the claim added anything
of significance to this natural law, the court concluded “Plaintiffs
cannot seriously contend that it is a new practice to exclude certain
patients from treatment with a drug when those patients are at an
increased risk of experiencing negative side effects from the drug.”
153
Thus, the claim was not patent eligible.
154
In contrast, the Federal Circuit in Vanda Pharmaceuticals Inc. v.
West-Ward Pharmaceuticals
155
held that a method of treating a patient
with schizophrenia by determining the patient’s capacity to metabolize
a particular enzyme and then administering a particular dosage of a
drug containing the enzyme based on that finding.
156
Despite the
similarity of the method claims in Vanda to those in Mayo itself, the
Federal Circuit held that the claims were not directed to a natural law
or phenomenon.
157
According to at least one commentator, “Vanda
precipitated a 180-degree turn in how district courts deal with patent-
eligibility challenges to method of treatment claims. Whereas pre-
Vanda the district courts typically found these claims to be directed to
a law of nature under step one [of Mayo], they now uniformly find
them patent-eligible under step one and do not proceed to step two.”
158
Likewise, the USPTO has issued guidance stating that, consistent
151. Id.
152. Id. at *60.
153. Id. at *54.
154. Id. at *60.
155. Vanda Pharms. Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117 (Fed. Cir.
2018).
156. Id.
157. Id. Judge Prost dissented from the decision, pointing out the clear analogy
to the claims in Mayo. Id.
158. Thomas Hedemann & David Ludwig, Method-Of-Treatment Patent
Eligibility: Step 1 And Done? LAW360, Feb. 5, 2019.
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with Vanda, “method of treatment claims that practically apply natural
relationships should be considered patent eligible under Step [1] [of
Mayo].”
159
Most recently, the Federal Circuit in Endo
Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
160
upheld the
eligibility of another personalized method of treatment claim
involving the dosing of a particular drug based on a patient’s metabolic
characteristics.
Given these developments, the current trend in the U.S. appears to
be to recognize the patentability of medical treatment claims, subject
only to the limited healthcare practitioner immunity under Section
287(c).
E. OTHER JURISDICTIONS AND LIMITS ON PATENTABILITY OF
MEDICAL TREATMENT
In addition to the jurisdictions discussed above, some jurisdictions
that have not expressly adopted statutory limitations on the patenting
of medical treatments have limited such patents through judicial
doctrine. In Canada, for example, the Canadian Patent Act does not
expressly exclude medical treatments from patentability.
161
However,
the Canadian Supreme Court has rejected patents covering medical
treatments when the claimed method “does not lay in the field of the
manual or productive arts nor, when applied to the human body, does
it produce a result in relation to trade, commerce or industry, or a result
that is essentially economic.”
162
In effect, this approach resembles the
159. Robert W. Bahr,Memorandum to Patent Examining Corps - Recent Subject
Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward
Pharmaceuticals (Jun. 7, 2018).
160. Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.
2019).
161. See Canada Patent Act, R.S.C. 1985, c P-4 (authorizing the use of a patented
invention only if “the Minister of Health has notified the Commissioner that the
version of the pharmaceutical product that is named in the application meets the
requirements of the Food and Drugs Act and its regulations, including the
requirements under those regulations relating to the marking, embossing, labeling
and packaging that identify that version of the product as having been
manufactured . . . in a manner that distinguishes it from the version of the
pharmaceutical product sold in Canada by, or with the consent of, the patentee or
patentees”).
162. Apotex Inc. v. Wellcome Found. Ltd. [2002] S.C.R. 153 (Can.) (“The policy
rationale . . . was that the unpatentable claim was essentially non-economic and
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pre-EPC approach taken by courts in the UK, which found that
medical treatments were not patentable due to their lack of industrial
application.
163
The Canadian Patent Office has adopted this judicial
reasoning in its examination procedures and now rejects patent claims
seeking to cover methods that provide a practical therapeutic effect,
such as curing, preventing, or ameliorating an ailment or pathological
condition, or treating a physical abnormality or deformity, such as by
physiotherapy or surgery.
164
Likewise, though New Zealand did not statutorily limit the
patentability of medical treatments until recently,
165
the New Zealand
courts consistently held that methods of treatment of human disease
do not meet the requirement that patentable methods describe a
manner of manufacture.
166
The one developed jurisdiction that appears most willing to grant
and enforce medical treatment patents is Australia. The Australian
Federal Court first confirmed the patentability of medical treatment
methods in 1994 inAnaesthetic Supplies v. Rescare and confirmed this
result in 2000 in Bristol Myers Squibb v. F H Faulding.
167
The Court’s
unrelated to trade, industry, or commerce. It was related rather to the area of
professional skills.”); Tennessee Eastman v. Commissioner of Patents [1974] S.C.R.
111 (Can.); Commissioner’s Decision, No. 197, at 2 (1974) (Can.), http://brevets-
patents.ic.gc.ca/opic-cipo/comdec/eng/decision/194/image.html?page=1&scale=
0.25&rotation=0 (“Having come to the conclusion that methods of medical
treatment are not contemplated in the definition of ‘invention’ as a kind of
‘process.’”).
163. David Letham & Richard Scott, The Doctrine of Equivalents Reaches the
UK 1–2 HOFFMANN EITLE, https://www.hoffmanneitle.com/wp-content/uploads/
The-Doctrine-Of-Equivalents-Reaches-the-UK.2-1.pdf.
164. CAN. INTELL. PROP. OFF., PATENT OFFICE MANUAL OF PATENT OFFICE
PRACTICE (2018), https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/vwapj/
rpbb-mopop-eng.pdf/$file/rpbb-mopop-eng.pdf (explaining that section 17.03.01
notes, however, that “removal of the medical aspect of a claim may render [the
claim] acceptable”).
165. Patents Act 2013, s 2 (N.Z.) (“An invention of a method of treatment of
human beings by surgery or therapy is not a patentable invention.”).
166. Swift & Co. [1960] NZIPOPAT 1 (1960) (N.Z.); Wellcome Found. Ltd. v.
Comm’r of Patents [1983] NZCA 385 (N.Z.); Susy Frankel, Intellectual Property in
New Zealand and the TPPA 173–74 (Victoria Univ. of Wellington, Legal Research
Paper No. 37, 2012) (“The Patent Bill before Parliament at the time of writing
includes some exceptions to patentability because these things should not be the
exclusive property of anyone.”).
167. Bristol-Myers Squibb Co. v. F H Faulding & Co. Ltd. [2000] FCA 316 (22
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decision in Bristol Meyers Squibb, a case involving a method of
administering the anti-cancer drug Taxol, is particularly telling. In that
case, the lower court, relying on a dissenting opinion in Rescare, held
that issuing a patent on the claimed treatment method was “generally
inconvenient” under the public policy proviso of the Australian Statute
of Monopolies, and that the patent was thus invalid.
168
The Federal
Court unanimously reversed the lower court’s decision, finding no
reason to deviate from its prior reasoning in Rescare. Most recently,
an Australian High Court again confirmed the patentability of methods
of treatment involving the administration of therapeutic drugs in
Apotex v. Sanofi-Aventis Australia.
169
Interestingly, each of these
decisions involved method claims describing the administration of a
therapeutic agent or drug. The Australian courts have yet to confirm
the patentability of purely medical or surgical procedures.
170
F. SUMMARY: METHODS OFMEDICAL TREATMENT
PATENTABILITY EXCLUSIONS
As shown in this Part II, numerous jurisdictions have limited the
ability of applicants to obtain patents onmethods ofmedical treatment.
The EPC expressly removes medical treatments from patentability and
has been followed by all EPC member states.
171
The TRIPS
Agreement and numerous other bilateral and multilateral trade
agreements allow signatory states to exclude medical treatments from
their national patent laws, and at least sixty states have taken
advantage of this flexibility to do so.
172
The United States, in contrast,
has adopted a unique statutory immunity from infringement for
medical practitioners and healthcare organizations, but it otherwise
likely to uphold patents on medical treatments. Other countries,
March 2000) ¶¶ 132–39 (Austl.).
168. Id. ¶¶ 5–7.
169. Apotex Pty. Ltd. v. Sanofi-Aventis Australia Pty. Ltd. [2013] HCA 50 (4
December 2013) (Austl.).
170. It is important to note that medical treatments are not always patentable
under Australian law. Each patent claim must be addressed on a case-by-case basis.
See, e.g., id.
171. EPC art. 53(c), supra note 100.
172. World Intellectual Prop. Org. [WIPO], Exclusions from Patentable Subject
Matter and Exceptions and Limitations to the Rights, at 58, WIPO Doc. SCP/15/3
(Jan. 1, 2010); Mitnovetski & Nicol, supra note 87, at 470.
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though they have not enacted specific legislation limiting medical
treatment patents, have taken a range of judicial positions that have
failed to uphold such patents on grounds of lack of industrial
application. As a result, the patentability of medical treatments is
effectively prohibited or limited throughout much of the developed
world.
III. ARE CAR-T AND OTHER GENE THERAPIES
PATENTABLE?
Given the extensive limitations on patenting medical treatments
around the world, we ask whether CAR-T and other gene therapies
discussed in Part I should be considered medical treatments subject to
such limitations. In analyzing this question, it is important first to
develop a more detailed understanding of the definition “medical
treatment.” While we are unaware of any court or agency decision
applying this definition specifically to CAR-T therapies, several
useful discussions exist in the case law and literature.
A. METHODS OFMEDICAL TREATMENT UNDER THE EPC
EXCLUSION
As described in Part II.B, Article 53(c) of the EPC excludes medical
treatments from patent protection on grounds of ordre public and
morality.
173
Over the years, the courts and the European Patent Office
(EPO), including the EPO’s Boards of Appeal,
174
have interpreted the
Article 53(c) exclusion (including its precursor under Article 52[4])
and its subcomponents. In this Part III.A, we discuss the decisions of
these bodies inasmuch as they are relevant to the patentability of gene
and cell therapies, which we take up specifically in Part III.B,
173. Mitnovetski & Nicol, supra note 87, at 472.
174. Decisions of the EPO are reviewed by one of twenty-eight Technical Boards
of Appeal, with appellate recourse to an Enlarged Board of Appeal. See About the
Boards of Appeal, EUR. PAT. OFF., https://www.epo.org/law-practice/case-law-
appeals/about-the-boards-of-appeal.html (last visited Feb. 12, 2019). Decisions of
the EPO are not strictly binding on national courts, which have the ultimate authority
to interpret their national patent statutes and to assess the patentability of inventions
under those statutes. However, decisions of the EPO, and its Board of Appeal in
particular, are viewed as highly informative to national courts interpreting their
national laws implementing the EPC.
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below.
175
1. Performance by a Medical Practitioner
The EPO Boards of Appeal have defined the term “medical
treatment” as “any non-insignificant intentional physical or psychic
intervention performed directly or indirectly by one human being—
who need not necessarily be a medical practitioner—on another . . .
using means or methods of medical science.”
176
The Boards of Appeal
have explained that a medical treatment need not be carried out by a
physician in other to fall within the exclusion.
177
However, the Boards
have also suggested that there is a strong presumption that a method is
excluded under the EPC when that method has to be performed by a
physician or under his or her supervision.
178
2. Practiced on the Human Body
To fall within the exclusion provided under EPC Article 53(c), the
method of treatment must be “practised on the human or animal
body.”
179
However, Article 53(c) “does not require a specific type and
175. For a comprehensive discussion of the EPC’s medical treatment exclusion,
see STERCKX&COCKBAIN, supra note 102, at 135–71.
176. Case T 0182/90 (Blood flow), ECLI:EP:BA:1993:T018290.19930730, ¶ 2.2
(July 30, 1993), https://www.epo.org/law-practice/case-law-appeals/recent/
t900182ex1.html.
177. Id.; see STERCKX&COCKBAIN, supra note 102, at 156.
178. Case T 0024/91 (Cornea), ECLI:EP:BA:1994:T002491.19940505, ¶ 2.4
(May 5, 1994), https://www.epo.org/law-practice/case-law-appeals/recent/
t910024ex1.html (“[W]here, in view of the health risks connected with such a
treatment, a claimed method for treatment has to be performed by a physician or
under his supervision, it will normally fall within the exclusion of the first sentence
of Article 52(4) EPC.”); Case T 0329/94 (Blood extraction method),
ECLI:EP:BA:1997:T032994.19970611, ¶ 5 (June 11, 1997), https://www.epo.org/
law-practice/case-law-appeals/recent/t940329ex1.html (“This sole criterion is not
sufficient to decide whether the method step is objectionable under Art. 52(4) EPC,
though the medical competence of the practitioner may be, at first sight, a useful
indication. Much more important are the purpose and inevitable effect of the feature
under consideration.”).
179. Guidelines for Examination in the European Patent Office, EUR. PAT. OFF.,
at Part G, ch. 2, § 4.2.1 (2018), http://documents.epo.org/projects/babylon/eponet.
nsf/0/2A358516CE34385CC125833700498332/$File/guidelines_for_examination
_2018_hyperlinked_en.pdf.
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intensity of interaction with the human or animal body.”
180
According
to the EPO Boards of Appeal, a method claim falls under the
prohibition if it includes at least one feature defining a physical
activity or action that constitutes a method step for treatment of the
human or animal body by surgery or therapy.
181
Indeed, according to
the EPO Boards of Appeal, “[T]he surgical or therapeutic nature of a
method claim can perfectly be established by a single method
step. . . .”
182
This “single step” threshold is also recognized in the
November 2018 edition of the EPO Guidelines for Examination.
183
However, claims that disclose methods carried out fully in vitro,
without requiring that at least one of the steps be practiced on the
human or animal body, do not fall within the Article 53(c)
exception.
184
Thus, as explained by Sterckx and Cockbain,
It has long been clear that ex vivo diagnostic methods (e.g. diagnostic tests
performed on blood samples) as well as the substances and equipment used
by physicians and veterinary surgeons in the course of diagnosis, therapy
and surgery, were not and are not excluded from patentability.
185
3. Surgery or Therapy
In order to be excluded from patentability, Article 53(c) requires
180. See, e.g., Case G 0001/04 (Diagnostic methods),
ECLI:EP:BA:2005:G000104.20051216, ¶ 6.4.2 (Dec. 16, 2005),
https://www.epo.org/law-practice/case-law-appeals/recent/g040001ex1.html (“It
follows that each and every one of these method steps satisfies the criterion
‘practised on the human or animal body’ if its performance implies any interaction
with the human or animal body, necessitating the presence of the latter.”).
181. Id. This principle is known as the “contamination” approach, as any single
medical treatment step will “contaminate” the entire claim and render it
unpatentable. STERCKX & COCKBAIN, supra note 102, at 159 (“To have done
otherwise would have made a mockery of the exclusion—if cutting off a man’s leg
is surgery, then does giving him a cup of tea afterwards mean he has not undergone
surgery?”).
182. See Case G 0001/04 (Diagnostic methods), at ¶ 6.2.1; see also G 2/08, O.J.
EPO 2010, 456 at 476, ¶ 5.6. (“[A]ny method claim containing even a single step
pertaining by nature to a treatment by therapy is not allowable. This is established
case law.”).
183. Guidelines for Examination in the European Patent Office, supra note 179,
at Part G, ch. 2, § 4.2.1.
184. Case G 0001/04 (Diagnostic methods), at ¶ 6.4.3. (“[T]his criterion is neither
complied with in respect of method steps carried out in vitro in a laboratory.”).
185. STERCKX&COCKBAIN, supra note 102, at 158.
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that the method of treatment be implemented by means of “surgery or
therapy.”
186
Several forms of medical intervention have been
considered by the EPO Boards of Appeal to fall within the meaning of
the term “therapy” for purposes of applying this exception. The Board
has applied this exception to patent applications claiming curative
therapies, or methods for the healing of diseases,
187
but also for
methods aimed at relieving pain, or symptomatic therapy,
188
and
methods designed to prevent diseases from occurring, also known as
prophylactic therapy.
189
4. Removal from the Body
The EPO Guidelines for Examination explain that the treatment of
body tissue or fluids “after they have been removed from the human
or animal body, or diagnostic methods applied thereon, are not
excluded from patentability as long as these tissues or fluids are not
returned to the same body.”
190
By the same reasoning, the treatment of
body tissue or fluids that are returned to the same body are subject to
the exclusion contained in Article 53(c).
191
An example given by the
EPO Guidelines involves fluids removed from the body: the treatment
of blood for storage in a blood bank or diagnostic testing of blood
samples are generally not excluded from patentability, while the
treatment of blood by dialysis with the blood being returned to the
same body, are generally excluded from patentability under Article
53(c).
192
Accordingly, it is the return of tissues or fluids to the same
body fromwhich theywere originally taken that bring a process within
186. See id. at 138–52 (discussing cases defining therapy and surgery).
187. Case T 0019/86 (Pigs II), ECLI:EP:BA:1987:T001986.19871015, ¶ 8 (Oct.
15, 1987), https://www.epo.org/law-practice/case-law-appeals/recent/
t860019ep1.html.
188. Case T 0081/84 (Dysmenorrhea), ECLI:EP:BA:1987:T008184.19870515, ¶
4 (May 15, 1987), https://www.epo.org/law-practice/case-law-appeals/recent/
t840081ex1.html.
189. See Case T 0019/86 (Pigs II), at ¶ 7.
190. Guidelines for Examination in the European Patent Office, supra note 179,
at Part G, ch. 2, § 4.2.1.
191. Id.
192. Id. (“Thus the treatment of blood for storage in a blood bank or diagnostic
testing of blood samples is not excluded, whereas a treatment of blood by dialysis
with the blood being returned to the same body would be excluded.”).
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the patentability exclusion of Article 53(c).
193
5. Product versus Process Claims
Much of the controversy surrounding medical treatment patents has
arisen with respect to methods of administering particular drugs (i.e.,
patient selection, dosing regimen, etc.). While Article 53(c) of the EPC
prohibits the patenting of medical treatments, it expressly does not
apply to “products, in particular substances or compositions, for use
in any of these methods.”
194
As explained by the EPO Enlarged Board
of Appeals,
The provisions of Article 53(c) EPC are clear and unambiguous, drawing a
borderline between unallowable method claims directed to a therapeutic
treatment on the one hand and allowable claims to products for use in such
methods on the other hand . . . [Thus,] in respect of claims directed to
therapy, method claims are absolutely forbidden in order to leave the
physician free to act unfettered, whereas product claims are allowable
provided their subject-matter be new and inventive.
195
Despite the seeming clarity of this distinction, the division between
treatment methods and products became blurred in the case of patent
claims covering methods for the administration of particular drugs,
especially drugs that were themselves unpatented.
196
This issue was
addressed, to a degree, in the 2000 amendments to the EPC, which
added Article 54(5) providing that methods of treatment involving a
new use of a known substance were amenable to patent protection,
notwithstanding the limitations of Article 53(c).
197
The EPO Enlarged
Board of Appeal has since clarified that such new uses can encompass
any “specified new and inventive therapeutic application” (e.g., new
193. Id.
194. EPC art. 53(c), supra note 100.
195. See G 2/08, OJ EPO 2010, at 477, ¶ 5.7.
196. CARLOSCORREA, GUIDELINES FOR THEEXAMINATION OFPHARMACEUTICAL
PATENTS: DEVELOPING A PUBLIC HEALTH PERSPECTIVE – A WORKING PAPER 16
(Jan. 27, 2007), http://apps.who.int/medicinedocs/documents/s21419en/
s21419en.pdf.
197. EPC art. 54(5), supra note 100 (“Paragraphs 2 and 3 [relating to novelty]
shall also not exclude the patentability of any substance or composition [comprised
in the state of the art] for any specific use in a method referred to in Article 53(c),
provided that such use is not comprised in the state of the art.”). See STERCKX &
COCKBAIN, supra note 102, at 159.
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dosage regimes) and need not be drawn to entirely new diseases than
the substance was previously known to address.
198
B. APPLYING THE EPC PATENTABILITY EXCLUSION TOGENE
THERAPIES
Article 53(c) of the EPC has important implications for the
patentability of gene and cell therapies at the EPO. In this Part, we
analyze the features of CAR-T patent claims in view of the
patentability exclusion under EPC Article 53(c) and conclude that
such claims are largely encompassed by this exclusion. It seems that
we are not alone in this assessment: even representatives of the
biopharmaceutical industry appear to recognize that gene and cell
therapies such as CAR-T are better characterized as medical
procedures than drugs, which then leads to the question of what type
of intellectual property protection, if any, applies. During a panel of
the Fifth Global Congress on Intellectual Property and the Public
Interest, Joseph Damond, Senior Vice President of the Biotechnology
Industry Organization (BIO), stated:
What I’m concerned about, then, is not just where we stand now, but where
the future of the industry is going. Because, if you look at those pipelines,
what’s being done right now are things like gene therapy and cell therapy,
where you take your blood and give it to a company and they modify your
DNA to correct for mutations and they give it back to you, which looks
more like a service, actually, than a drug. And what’s the IP on that?
199
The remainder of this Part explores this question.
1. In vivo versus in vitro procedures
Gene therapies involve introducing, removing or changing the
198. See G 2/08, OJ EPO 2010, at 485, ¶ 5.10.5. Prior to the 2000 EPC
amendments and the EPO Enlarged Board of Appeal’s decision in G 0002/08, many
applicants drafted claims for new uses of known substances in terms of a
manufacturing process for the substance (so-called “Swiss-type claims”). The Board
eliminated the permissibility of such Swiss-type claims in G 0002/08 given the
clarified language of EPC Article 54(5). G 2/08, OJ EPO 2010, at 492, ¶ 7.1.3.
199. O’Neill Institute, Global Congress on Intellectual Property & The Public
Interest, YOUTUBE (Oct. 10, 2018), https://www.youtube.com/watch?v
=OkuSLYIxqbg&feature=youtu.be&t=2175.
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content of a person’s genetic code.
200
Cell therapy involves
administering living cells to a patient.
201
Therefore, patent claims
covering gene and cell therapies are often drafted using methods
claims where at least one of the steps is performed in vivo.
202
In such
cases, these method claims, including methods of performing CAR-T
therapy, can be considered methods “practiced on the human or animal
body,” therefore falling under the exclusion provided in EPC Article
53(c).
203
Although gene and cell therapies, including CAR-T, may also
involve ex vivo steps in which genes and cells are harvested or
modified outside the human body, EPC Article 53(c) does not require
all of the method steps to be practiced on the patient in order to be
considered a method of treatment.
204
As the EPO Boards of Appeal
has explained, “the surgical or therapeutic nature of a method claim
can perfectly be established by a single method step. . . .”
205
It is precisely one of the method steps, the reintroduction of the cells
to the same patient from which they were previously extracted, that
better illustrate why CAR-T method patent applications likely fall
under EPC Article 53(c). As noted in Part II.A.4 above, the EPO
Guidelines distinguish between methods that only involve extracting
body tissues or fluids frommethods that also involve reintroducing the
extracted tissues or fluids to the same patient, such as dialysis.
206
The
last example closely resembles the apheresis and cell infusion steps
that are required in CAR-T therapies.
207
200. Gene and Cell Therapy Defined, AM. SOC’Y GENE & CELL THERAPY,
https://www.asgct.org/education-legacy/gene-and-cell-therapy-defined (last visited
Feb. 13, 2019).
201. Id.
202. Gregory Ramina, Regulation and Oversight of Gene Therapy in the US,
REGULATORY FOCUS 2 (Feb. 2017), https://advanced.jhu.edu/wp-content/uploads/
2017/03/gregoryRamina_regulationAndOversightOfGeneTherapyInTheUS.pdf.
203. EPC art. 53(c), supra note 100; Ramina, supra note 202, at 2.
204. EPC art. 53(c), supra note 100; Ramina, supra note 202, at 2.
205. Case G 0001/04 (Diagnostic methods),
ECLI:EP:BA:2005:G000104.20051216, ¶ 6.4.3 (Dec. 16, 2005),
https://www.epo.org/law-practice/case-law-appeals/recent/g040001ex1.html.
206. Guidelines for Examination in the European Patent Office, supra note 179,
at Part G, ch. 2, § 4.2.1.
207. What is the Process of Getting Treated with CAR T Cell Therapy?, BE THE
MATCH: CAR T CELL THERAPY, https://bethematch.org/patients-and-families/
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Despite the original focus of CAR-T patents on compositions of
matter,
208
there are numerous examples today of EPO applications for
CAR-T and other gene therapies that read in terms of methods of
treatment. For example, one claim of a 2014 PCT application
submitted by Dr. Carl June, a CAR-T pioneer at the University of
Pennsylvania, reads as follows:
A method for inducing at least a first and second epitope-specific immune
response in a cancer patient, the method comprising administering to a
patient in need thereof an effective amount of a cell genetically modified to
express a chimeric antigen receptor (CAR) comprising an antigen binding
domain, a transmembrane domain, and an intracellular signaling domain,
wherein the first epitope-specific immune response is directed to a target
epitope recognized by the CAR.
209
This claim encompasses (a) a method (b) for inducing an immune
response (c) by administering a cell genetically modified to express a
CAR, and (d) a description of the cell.
210
As such, this claim appears
highly susceptible to interpretation as a method of medical treatment.
There is at least one EPO application disclosing a CAR in which the
examiner raised Article 53(c) objections against two of the claims.
211
The first EPO opinion for this application rejected the claims,
reasoning that:
Claims 18 and 19 refer to a method of modulating the activity of a T
lymphocyte in vivo. This is considered as a method of treatment practiced
on the human or animal body. Pursuant to Art. 53(c) EPC, the subject-
matter of said claims is not regarded as being patentable. Consequently,
said claims should be either deleted or reformulated appropriately.
212
Following this opinion, the applicant amended its claims to
about-transplant/clinical-trials/car-t-cell-therapy/ (last visited Feb. 15, 2019).
208. See infra note 215 and accompanying text.
209. U.S. Patent Application No. 14/409,798 claim 1 (published Aug. 18, 2016).
210. Id. (claiming that an effective amount of genetically modified cells needs to
be administered to the patient to express a CAR).
211. European Patent Specification, European Patent Office App. No.
14751227.1, Publication No. EP2 956175B1, at 3 (published Oct. 4, 2017).
212. Examination, European Patent Office App. No. 14751227.1, ¶ 5.1 (filed on
Mar. 22, 2016), https://register.epo.org/application?number=EP14751227&lng=en
&tab=doclist (select “Search/examination” in drop down menu and then scroll down
to find a document dated “25.07.2016” and titled “European search opinion”).
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eliminate the term in vivo and replaced it with the term in vitro.
213
After
these changes, the application was allowed.
214
It appears that, in the
opinion of the examiner, amending the claims to suggest that that
specific step of the method was conducted “in vitro” as opposed to “in
vivo” was sufficient to avoid the “practised on the human . . . body”
threshold of Article 53(c).
215
This reasoning appears questionable.
Clearly, whatever alterations are made to the patient’s T-cells outside
of the body, the cells must eventually be returned to the patient’s body
to be effective. As such, the CAR-T process described in the claims
more closely resembles a procedure like dialysis (in which cells are
treated and then returned to the body) than storage of cells for
biobanking (in which cells are removed from the body and not
returned).
216
Simply diverting attention to the in vitro aspect of the
213. Claim 18 and 19 of EPO patent application EP2956175 currently reads as
follows:
18. A genetically modified cell according to claim 10 or 11 for use in a
method of treatment of a cancer in an individual, wherein the conditionally
active CAR is specific for an epitope on a cancer cell in the individual, and
wherein the method comprises: i) introducing the genetically modified cell
into the individual; and ii) administering to the individual an effective
amount of a dimerizing agent, wherein the dimerizing agent induces
dimerization of the heterodimeric, conditionally active CAR, wherein said
dimerization provides for activation of the genetically modified cell and
killing of the cancer cell, thereby treating the cancer.
19. A method of modulating the activity of a T lymphocyte host cell, the
method comprising contacting the host cell in vitro or ex vivo with a
dimerizing agent and a second member of a specific binding pair, wherein
the T lymphocyte is genetically modified to produce a heterodimeric,
conditionally active CAR of any one of claims 1 to 9, and wherein, in the
presence of the dimerizing agent and the second member of a specific
binding pair, the heterodimeric, conditionally active CAR dimerizes and
modulates at least one activity of the host cell.
European Patent Specification, European Patent Office App. No. 14751227.1, supra
note 211, at 149.
214. See Communication under Rule 71(3) EPC, European Patent Office App.
No. 14751227.1, Ref. No. AHB/FP7144538 (May 9, 2017).
215. Id.; EPC art. 53(c), supra note 100.
216. European Patent Specification, European Patent Office App. No.
14751227.1, supra note 211, at 149 (stating that a genetically modified cell is
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procedure does not eliminate all of its in vivo elements and, as noted
above, only one in vivo step of a process is required in order to classify
it as a medical treatment.
217
2. Process versus Product
Another question regarding the applicability of Article 53(c) to
CAR-T and other gene therapies is whether such technologies are
more likely to be classified as treatments or products. As noted in Part
II.B.5 above, the patentability exclusion of EPC Article 53(c) does not
apply to therapeutic compounds or substances, a compromise reached
during the negotiation of the EPC to preserve the patentability of
pharmaceutical products.
218
But as discussed above in this Part III.B,
CAR-T and other gene therapies resemble medical treatments in many
ways: they are designed to treat disease by taking action on a patient’s
body through the removal, treatment, and replacement of the patient’s
own cells.
219
In this regard, such therapies resemble dialysis and other
medical procedures that are generally acknowledged as excluded from
patentability under Article 53(c).
220
In fact, Kite Pharma, the developer
of Yescarta, explicitly describes its patents as covering “methods of
treatment” in its public securities filings.
221
introduced into the individual’s body as treatment for the cancer).
217. Furthermore, even in their current form, the application still appears to claim
steps that likely consist of a method of treatment, even if it now does not use the
term “in vivo.” That is the case, for example, with the phrase “introducing the
genetically modified cell into the individual” as provided in the current version of
the claims. European Patent Office Application No. 14751227.1, supra note 211, at
149. See Sherkow et al., supra note 13 (“[O]ur definition [of gene therapy] is
agnostic as to whether such modification takes place inside patient’s body or, as with
CAR-T, outside of it.”).
218. See Guidelines for Examination in the European Patent Office, supra note
179, at Part G, ch. 6, § 7.1.2; see also discussion supra Part II.B.5.
219. See Chimeric Antigen Receptor (Car) T- Cell Therapy, LEUKEMIA AND
LYMPHOMA SOC’Y, https://www.lls.org/treatment/types-of-treatment/
immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy (last visited Feb. 17,
2019); see also discussion supra Part III.B.
220. What is CAR-T Cell Therapy?, PENN. MEDICINE: ABRAMSON CANCER CTR.
(Dec. 4, 2017), https://www.pennmedicine.org/cancer/about/focus-on-cancer/2017/
december/defining-cart; Guidelines for Examination in the European Patent Office,
supra note 179, at Part G, ch. 2, § 4.2.1.
221. KITEPHARMA, INC., ANNUALREPORT (FORM 10-K) 16 (Feb. 28, 2017) (“Our
intellectual property estate strategy is designed to provide multiple layers of
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However, in their regulatory filings, the developers of CAR-T
therapies have gone to great lengths to refer to these therapies not as
medical treatments, but as products. For example, as discussed in Part
I.C, both the U.S. FDA and the EU EMA give considerable weight to
the “manufacturing” practices proposed for new gene therapies.
222
Novartis, in its FDA application for marketing approval of Kymriah,
consistently refers to Kymriah (tisagenlecleucel) as a “product” that is
“manufactured” at a facility in New Jersey,
223
much as a traditional
drug would be. The documentation published by the European
Medicine Agency (EMA) also describes Kymriah as a “product.”
224
This characterization of Kymriah as a product or drug, however, is
a fiction.
225
The “product” in question is a batch of the patient’s own
T-cells that are taken from the patient, altered, and then re-introduced
into the patient’s body.
226
This is not a manufactured product, but a
process performed ex vivo on the patient’s cells.
227
The “labeling” of a “product” like Kymriah pushes this fiction to its
protection, including: (1) patent rights with broad claims directed to core CAR
constructs used in our products; (2) patent rights covering methods of treatment for
therapeutic indications; (3) patent rights covering specific products; and (4) patent
rights covering innovative manufacturing processes, preconditioning methods, new
constructs and methods for genetically engineering T cells.”) (emphasis added).
222. RICHARD KINGHAM ET AL., BIOLOGICAL DRUG PRODUCTS: DEVELOPMENT
AND STRATEGIES 85, 92 n.65, 97–98 (Wei Wang & Manmohan Singh eds., 2014).
223. NOVARTISAPPROVAL LETTER, supra note 3, at 1.
224. European Medicine Agency [EMA], Annex I: Summary of Product
Characteristics, at 2, https://www.ema.europa.eu/documents/product-information/
kymriah-epar-product-information_en.pdf (last visited Feb. 17, 2019).
225. We recognize that the tendency for manufacturers to characterize their gene
therapies as “products” is also due to the statutory authority of the FDA, which
regulates products and their manufacture, but not medical procedures. But even if
there is an extrinsic reason pushing manufacturers to categorize these methods as
products, the classification is still, in our view, a fiction.
226. See id. at 39 (describing the process by which a physician will remove the
patient’s white blood cells, process them to make Kymriah, and then return the
substance to the patient’s body).
227. Id. at 2. This being said, we recognize that the producers of CAR-T and other
gene and cell therapies have drafted some of their patent claims to cover modified
T-cells and other biological compounds as compositions of matter. While these types
of claims might appear to avoid exclusion under the medical treatment provisions
discussed in this article, we suggest that the examining patent offices look past artful
claiming to the actual invention for which a patent is sought—in this case, a method
of medical treatment.
748 AM. U. INT’L L. REV. [34:4
limit, as the “product” in question is not sold or marketed to the public,
patients, pharmacists, or physicians, but rather is extracted from a
particular individual for eventual re-introduction to the donor
individual alone, and to no one else.
228
As such, the “packaging” in
which Kymriah is approved to be “marketed” is the intravenous
infusion bag used to reintroduce the modified T-cells to the patient’s
body.
229
This is hardly “marketing” of a product, given that no
individual—patient, pharmacist, or physician—need make any
purchasing or prescribing decision regarding the re-administration of
the modified T-cells back to the patient.
230
Thus, referring to a CAR-
T therapy such as Kymriah as a product that is packaged and marketed
simply mischaracterizes the nature of the therapy and inaccurately
conflates it with a drug product that is marketed and prescribed to
members of the public. While this characterization appears to be
acceptable to the FDA and EMAwhich encourages applicants to apply
the language of “products” to new gene therapies in its Guidance
documents,
231
this peculiar regulatory approach should not alter the
more accurate characterization of such gene therapies as medical
treatments under the patent laws, which stand quite apart from the
requirements for regulatory marketing approval.
C. CAR-T ANDGENE THERAPIES BEYOND THE EPC
As discussed in Part III.B above, CAR-T and other gene and cell
therapies should most likely be classified as medical treatments under
the EPC and thus excluded frompatentability under EPCArticle 53(c).
By the same token, such therapies should also be excluded from
patentability under other legal regimes that exclude patents onmedical
treatments, including (a) national implementations of EPC Article
53(c), (b) national patent laws that implement the flexibility to exclude
such patents under TRIPS Article 27(3) and other bilateral and
multilateral trade agreements, and (c) judicial precedents, such as
those in Canada and New Zealand, that exclude patentability of
228. See id. at 36, 39 (explaining the unique characteristics of Kymriah and how
the product is formed).
229. See id. at 39 (describing how Kymriah will be stored and labeled).
230. See id. at 36 (explaining how T cells are removed from your body, modified,
and then placed back in a patient’s body for the purpose of destroying cancer cells).
231. See INDS INFORMATION, supra note 33, at 1–2.
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medical therapies as lacking industrial application or as against ordre
public and morality. In addition, in the United States CAR-T and other
gene and cell therapies should trigger the immunity from infringement
for physicians and healthcare organizations under Section 287(c) of
the U.S. Patent Act.
Admittedly, outside of the EPC and U.S., there is little case law or
agency guidance regarding the scope of the medical treatment
exemption, and even less that informs its application to gene and cell
therapies. However, we believe that the detailed reasoning of the EPO
and its Boards of Appeal described in Part III.A is particularly useful
even to jurisdictions that are outside of the EPC.
232
In fact, certain non-
EPC legal regimes may offer national patent offices and courts even
greater latitude to exclude patents covering medical treatments than
does the EPC. For example, EPC Article 53(c), coupled with Article
54(5), creates an express carve-out for medical treatments that involve
the application of a novel application of a known drug. But this carve-
out does not exist in the TRIPS Agreement,
233
and TRIPS member
states that have elected to exclude patentability of medical treatments
may do so unreservedly, without permitting patents on treatments that
involve a drug.
234
IV. IMPLICATIONS AND OUTLOOK
In Part III above, we conclude that under the legal standards
prevailing in Europe, the United States, and numerous other countries,
CAR-T and other gene and cell therapies can be classified as medical
treatments that are not subject to patent protection. In this Part, we
examine the implications of this finding both for current practice and
future developments.
A. EXISTING CAR-T PATENTS: POST-GRANTCHALLENGES
As noted in Part II.C above, numerous patents have been issued,
232. See discussion supra Part III.A.
233. See TRIPS Agreement art. 27, supra note 111.
234. See Michael H. Davis, Excluding Patentability of Therapeutic Methods,
Including Methods Using Pharmaceuticals, for the Treatment of Humans Under
Trade Related Aspects of Intellectual Property Rights Article 27(3)(A), 43 HOFSTRA
L. REV. 185, 185–86 (2014).
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and many more applications have been filed around the world, to
protect CAR-T and other gene and cell therapies. If the analysis
contained in Part III is correct, then many, if not all, of these patents
are contrary to existing statutory exclusions of patentability under the
EPC and similar statutory regimes.
235
As such, it is likely that when
the owners of such patents assert them in litigation, they would be
subject to successful invalidity defenses by the alleged infringers.
236
However, even if such patents could successfully be challenged in
litigation, the existence of such patents “on the books,” even if invalid,
can itself significantly impact private behavior and chill productive
research and development of competing products. The situation is
complicated further if medical treatment patents are included in larger
patent portfolios that include both medical treatment patents as well as
patents covering drugs or medical devices that are not barred by
medical treatment patentability exclusions. For all of these reasons,
there is a recognized public interest in clearing the market of invalid
patents.
237
There are several existing mechanisms by which patents may be
challenged after grant. In Europe, issued patents may be challenged in
an opposition proceeding under Article 99 of the EPC.
238
Article 99
provides that “any person” may file an opposition seeking to invalidate
an issued European patent within nine months of its publication in the
European Patent Bulletin.
239
In addition to lack of disclosure and
patents granted with a subject-matter that extends beyond the content
of the application as filed, EPO oppositions can be filed when the
patent is not patentable under Articles 52 to 57 of the EPC, which of
course includes Article 53(c) regarding medical treatments.
240
235. Guidelines for Examination in the European Patent Office, supra note 179,
at Part G, ch. 2, § 4.2.1.
236. Id.
237. See Lear, Inc. v. Adkins, 395 U.S. 653, 670 (1969) (recognizing an
“important public interest in permitting full and free competition in the use of ideas
which are in reality a part of the public domain”).
238. EPC art. 99, supra note 100.
239. Given the recent advent of CAR-T and other gene and cell therapies, we
estimate that most patent applications covering these technologies are still being
examined at the EPO, and in most cases, the nine-month deadline to file oppositions
against prospective patents has not been triggered. Id.
240. Id.
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Issued patents may also be challenged in the United States using a
number of procedures before the Patent Trial and Appeals Board
(PTAB), including post-grant review (PGR)
241
and inter partes review
(IPR).
242
However, neither PGR nor IPR proceedings are relevant
vehicles for asserting the medical practitioner immunity granted under
Section 287(c) of the Patent Act (as this immunity is a defense to a
claim of infringement rather than a challenge to an asserted patent).
243
Thus, in the United States, the only viable means for challenging the
enforcement of medical treatment patents is likely to be an immunity
defense under Section 287(c).
Traditionally in the United States, Europe, and elsewhere, only a
patentee’s direct competitors have had sufficient incentives to monitor
and challenge patents in oppositions and other post-grant
proceedings.
244
However, recent years have seen the emergence of
public watchdog entitles such as Unified Patents that raise funding to
challenge questionable patents in a range of technology markets (e.g.,
mobile devices, automotive technology, Internet of Things, etc.).
245
Given that the cost of mounting an opposition or post-grant challenge
to patents is significantly lower than the cost of patent litigation in
general, it is possible that entities may emerge to challenge
questionable patents in the gene and cell therapy sector as well, at least
in Europe and other jurisdictions in which the validity of such patents
is in doubt.
246
B. FUTURE EXAMINATIONGUIDANCE
Given the recent advances in CAR-T and other gene and cell
therapies, patents covering these techniques are still relatively young.
241. 35 U.S.C. § 321 (2017).
242. Id. § 311.
243. Id. § 287.
244. See Susan J. Marsnik, Will the America Invents Act Post-Grant Review
Improve the Quality of Patents? A Comparison with the European Patent Office
Opposition, U. ST. THOMAS: ETHICS & BUS. L. FACULTY PUBL’N (2012),
http://ir.stthomas.edu/ocbeblpub/25 (discussing empirical studies about what
triggers opposition in the EPO and the United States and how the opposition creates
a societal benefit by reducing the number of invalid patents).
245. See What is Unified?, UNITED PATENTS, www.unifiedpatents.com.
246. Sapna Kumar, Standing Against Bad Patents, 32 BERKLEYTECH. L.J. 87, 91,
94 (2018).
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Thus, while there are comparatively few issued patents covering these
techniques today, a large number of patent applications is likely
pending in the examination process around the world, a number that is
likely to increase over time. If such techniques are not eligible for
patent protection under applicable statutory and judicial limitations on
patentability of medical treatments, then it would be far more efficient
for examining patent offices to deny the issuance of patents on such
claims, rather than issuing such patents and waiting for them to be
invalidated in adversarial proceedings such as oppositions and IPRs.
Yet surprisingly few patent offices have, to date, evidenced careful
consideration of patentability limitations on such technologies,
possibly because applicants have characterized them as products
rather than medical treatments.
247
Accordingly, the time is ripe for
patent offices around the world to consider the patentability of CAR-
T and other gene and cell therapies in view of national statutory and
judicial limitations on the patentability of medical treatments. Such
guidance is valuable both to individual patent examiners considering
complex technical applications, as well as to the industry and patent
bar.
Thus, we would recommend that the EPO move rapidly to publish
definitive guidance regarding the patentability of CAR-T and other
gene and cell therapies in the Guidelines for Examination, and that the
USPTO do the same in its Manual of Patent Examination Procedures
(MPEP). With leading patent offices issuing such guidance, patent
offices in other jurisdictions will have the opportunity to consider the
proper interpretation of their own laws and regulations in this area.
The lack of such guidance, however, can have a contagious effect, as
patent offices that unwittingly allow such applications in
contravention of their own laws may then lead other patent offices
considering PCT applications for the same inventions to issue patents
that are contrary to their own laws without due consideration.
C. POTENTIAL STATUTORYAMENDMENTS
If, as we contend, CAR-T and other gene and cell therapies are
247. See EMA, Annex I: Summary of Product Characteristics, supra note 224, at
2 (specifying that Kymriah is a product and listing it as such rather than referring to
it as a medical treatment).
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found in Europe and other jurisdictions not to be eligible for patent
protection under existing statutory and judicial limitations on
patenting medical treatments, then it is likely that a strong response
from the biopharmaceutical industry will ensue. Such responses are
not without precedent and have led, among other things, to legislative
concessions including the 2000 amendments of the EPC,
248
the Hatch-
Waxman Act in the United States,
249
and numerous pro-industry
concessions in TRIPS and other international trade agreements.
250
In
fact, lobbying for legislative reform to counter or reverse unpopular
statutory, regulatory or judicial rules is a common tactic across
industries.
As recent negotiations over intellectual property in various bilateral
and multilateral trade agreements have shown, legislatures in a
number of countries have proven willing to make concessions in order
to satisfy the demands of major trading partners such as the United
States.
251
Thus, it is not unlikely that some jurisdictions that currently
have statutory or judicial limitations on the ability to patent medical
treatments will, in the future, consider legislation designed to limit or
overturn those limitations, at least with respect to CAR-T and other
gene and cell therapies.
As these jurisdictions consider such legislation, we would urge
them to recall the important countervailing considerations promoting
public health and the unfettered ability of physicians to treat patients.
The biopharmaceutical industry is likely to oppose any formalized
limitation on the ability to patent CAR-T and other gene and cell
therapies with recourse to well-known arguments regarding the need
to incentivize biomedical research and development (R&D) through
248. See STERCKX&COCKBAIN, supra note 102, at 62–66.
249. 21 U.S.C. § 355(j) (2017).
250. See, e.g., Ebenezer Tetteh, Pharmaceutical Innovation, Fair Following and
the Constrained Value of TRIPS Flexibilities, 14 J. WORLD INTELL. PROP. 202, 208
(2011) (“OECD nations with ethical pharmaceutical firms have taken a pro-industry
stance—and understandably so, given difficulties of balancing industrial policies,
macroeconomic and health policy objectives—to impose TRIPS-plus conditions via
bilateral and region-free trade arrangements.”).
251. See United States-Mexico-Canada Agreement, Sept. 30, 2018, ch. 20, OFF.
U.S. TRADE REPRESENTATIVE, https://ustr.gov/trade-agreements/free-trade-
agreements/united-states-mexico-canada-agreement/agreement-between.
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patent-based exclusivity.
252
This argument, which is not wholly
without merit, posits that the exclusivity afforded by patents is
necessary to enable drug and device developers to recoup their high
costs of R&D, and that without the opportunity to charge monopoly
rents during this exclusive period and block market entry by lower-
priced competitors, developers would have little incentive to discover
and develop new lifesaving drugs and devices.
253
Certainly, some ability to recoup R&D costs and avoid immediate
competition from free riders is necessary for private sector
pharmaceutical developers to remain viable. However, pricing in the
pharmaceutical market today is not based on a cost-recovery model.
Rather, pharmaceutical firms appear to develop pricing strategies
based on what the market will bear, or the value that the market places
on their products.
254
This approach is nowhere more evident than in
the field of gene and cell therapy. As discussed in the Introduction,
CAR-T treatments such as Kymriah and Yescarta are priced at
US$475,000 and US$373,000 per treatment, respectively.
255
The
upward trend in pricing of gene therapies is likely to continue, as
indicated by Novartis’s recent announcement that $4-5 million per
patient would be a “cost effective” price for a new gene therapy under
development for spinal muscular atrophy (SMA).
256
Yet the incremental cost of providing such treatments has been
estimated by CAR-T pioneer Carl June to be in the range of $15,000.
257
252. See Sara Parker-Lue et al., The Ethics and Economics of Pharmaceutical
Pricing, 55 ANN. REV. PHARMACOLOGY&TOXICOLOGY 191, 197 (2014).
253. Many of the assertions inherent in these arguments are contested. See, e.g.,
Vinay Prasad & Sham Mailankody, Research and Development Spending to Bring
a Single Cancer Drug to Market and Revenues After Approval, 177 J. AM. MED.
ASS’N INTERNALMED. 1569, 1569–75 (2017); Parker-Lue et al, supra note 252, at
197; Marc-Andre Gagnon & Joel Lexchin, The Cost of Pushing Pills: A New
Estimate of Pharmaceutical Promotion Expenditures in the United States, 5 PLOS
MED. 29, 29 (2008), https://journals.plos.org/plosmedicine/article?id=10.1371/
journal.pmed.0050001.
254. See Richard G. Frank & Paul B. Ginsburg, Pharmaceutical Industry Profits
and Research and Development, HEALTHAFFAIRS, Nov. 12, 2017.
255. See Kolata, supra note 2; Beasley, supra note 7.
256. Miller, supra note 8.
257. Final Meeting Summary of the 8th Cell Therapy/FDA LiaisonMeeting, INT’L
SOC’Y FOR CELLULAR THERAPY (2018), https://cdn.ymaws.com/
www.celltherapysociety.org/resource/resmgr/files/PDF/Meetings/CTLM/October_
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Moreover, a significant portion of the R&D that contributed to the
discovery of CAR-T and other gene and cell therapies can be attributed
to basic research funded by government and philanthropic sources. For
example, in the United States, through July 2017 the National
Institutes of Health have funded 365 research projects involving
chimeric antigen receptors amounting to US$204 million in financial
support.
258
Of course, we acknowledge that basic scientific research,
such as that funded by the federal government, is not sufficient to
develop, test and bring a safe and efficacious therapeutic to market.
Even conservative estimates place the fully-loaded cost of developing
a new cancer therapy in the neighborhood of $650 million,
259
with
others estimating as high as $2.7 billion.
260
Nevertheless, there is
ample evidence that the high prices of today’s gene therapies are based
not on their cost of development or production, but on the price that
the market will bear.
261
2008/October_17_2008_Cell_Therapy_Liaison_Meeting_Summary_FINAL.pdf
(“Dr. June reviewed their approach to adoptive T cell therapy and clinical scale
expansion which costs in excess of $15,000 per patient.”); Donald B. Kohn et al.,
CARs on Track in the Clinic, 19 MOLECULAR THERAPY 432, 436 (2010) (“With
respect to financial considerations, Steven Rosenberg estimated that the full costs at
the NCI Surgery Branch to produce and release an autologous gene-engineered T-
cell product, including all laboratory supplies and reagents, staff salaries, and
product certification assays, amount to about $15,000 per treated patient (others
suggested somewhat higher costs per patient, in the range of $20,000 to $25,000, in
part based on differing costs for vector production and qualification). These costs do
not cover capital depreciation, overhead, and rental costs; however, the estimates
compare favorably with the procurement costs for unrelated allogeneic stem cell
products for clinical transplantation.”).
258. James Love, Federal Funding to Organizations for Projects Related to
Chimeric Antigen Receptors, KNOWLEDGE ECOLOGY INT’L (July 25, 2017),
https://www.keionline.org/23838 (basing the number of projects on a study of the
NIH RePorter database as of July 2017).
259. Prasad & Mailankody, supra note 253.
260. Joseph A. DiMasi et al., Innovation in the pharmaceutical industry: new
estimates of R&D costs, 47 J. HEALTH ECON. 20 (2016).
261. For example, Pascal Touchon, Senior Vice President of Novartis Oncology,
has publicly stated that “When we considered the price of tisagenlecleucel
[Kymriah] in the United States, the first thing we looked at was its medical value
and the value it brings to patients . . . Then we looked at the value to the health-care
system and society.” Jo Cavallo, Weighing the Cost and Value of CAR T-Cell
Therapy, ASCO POST (May 25, 2018), http://www.ascopost.com/issues/may-25-
2018/weighing-the-cost-and-value-of-car-t-cell-therapy/.
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At price levels such as these, lifesaving gene and cell therapies may
be unaffordable to many, including both uninsured and underinsured
individuals in private insurance jurisdictions such as the United States,
and to large swaths of the population in subsidized and national
healthcare systems. Although patents are not, in themselves, the
causes of exorbitant pricing for CAR-T and other gene and cell
therapies, patents enable developers to charge any price that the
relevant market will bear. Governments that face the decision of
whether to allow patents on gene therapies or not should always put
monopolies, rather than patients, at risk. Giving the fact that the
business model of private sector pharmaceutical developers relies, at
least in part, on obtaining these patents, we recognize that fully
exercising this patentability exclusion could lead to a broader debate
on how to induce private investments in these new therapies. While
that debate falls outside the scope of this paper, we believe that the
discussion should be based on alternative mechanisms for inducing
innovation, such as progressive delinkage, and not about eliminating
limitations on patentable subject matter to include gene therapies.
262
V. CONCLUSIONS
More than eighty countries, including the members of the European
Patent Convention, the United States, Canada, New Zealand, China,
Japan, and India, currently exclude or limit the patentability of
methods of medical treatment. CAR-T and other recent gene and cell
therapies, which operate based on the extraction of genetic or cellular
material from a patient, the alteration of such material, and the
reintroduction of such material to the patient’s body, have been
characterized by their developers as products. Yet this characterization
is largely a fiction. These therapies are more akin to medical
262. Delinkage “describes the idea that temporary monopolies and the associated
high drug prices should not be used to fund pharmaceutical research and
development, as well as a set of policy proposals that would replace monopolies and
high prices with alternative incentives based upon cash rewards, and expanded
funding for research, drug development, and clinical trials through a combination of
grants, contracts, tax credits, and other subsidies.” Progressive de-linkage means
that governments implement reforms over time that sequentially and progressively
move prices closer and closer to affordable generic prices, and reform incentives so
they no longer rely upon high prices. See What is Delinkage?, DELINKAGE.ORG (Feb.
28, 2016), https://delinkage.org/overview/.
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treatments such dialysis than manufactured products and should thus,
under most or all of these legal regimes, be excluded from
patentability, or be subject to limited patent enforcement.
Accordingly, we urge national patent offices to update their
examination procedures and practices to take these patentability
limitations into account and to publish guidance clearly explaining this
approach to applicants.
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APPENDIXA
International Trade Agreements Including Exclusion of Medical
Treatment Patents
Canada – Korea (article 16.12)
China – Korea (article 15.15)
Colombia – EFTA (article 6.9)
EU – CARIFORUM (article 148)
Japan – Switzerland (article 117)
Korea – Australia (article 13.8)
Korea – Vietnam (article 12.7)
NAFTA 1992 (article 1709)
Peru – EFTA (article 6.9)
Switzerland – China (article 11.8)
USA – Australia (article 17.9)
USA – Bahrain (article 14.8)
USA – Jordan (article 4.18)
USA – Oman (article 15.8)
US–DR–CAFTA (article 15.9)
US – Colombia (article 16.9)
US – Peru (article 16.9)
TPP/CPTPP (article 18.37)
USMCA (article 20.36.3(b))
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APPENDIXB
Countries Implementing Exclusion for Medical Treatment Patents
in National Legislation
1. Argentina: Article 6(e) of Law 24.481 enacted on March 1995
2. Albania: Article 6.4 of Law No. 9947 enacted on July 7, 2008
as amended up to Law No. 55/2014 of May 29, 2014
3. Andean Community: Article 20(d) of Decision No. 486
Establishing the Common Industrial Property Regime, adopted on
September 13, 2000
4. Bahrain: Article 3(d) of Law No. 1 of 2004 on Patents and
Utility Models, enacted up to January 23, 2004
5. Barbados: Article 11(c) of the Patents Act 2001, enacted July
25, 2001 as amended by Act No. 2 of 2006
6. Belgium: Section 7.2 of the Patent Law of March 28, 1984, as
amended up to December 22, 2008
7. Brunei Darussalam: Section 16 of the new Patents Act (2011)
8. China: Article 25 of the Patent Law
9. Chile: Article 37(d) of Law No. 19.039 on Industrial Property,
consolidated text as of February 6, 2012
10. Costa Rica: Article 1.4(b) of Law 6867 enacted on April 1983
and last amended on November 2008
11. Croatia: Article 6.3 of the Patent Act, enacted on October 14,
2003
12. Ecuador: Article 273.2 of the Organic Code on the Social
Economy of Knowledge, Creativity and Innovation, enacted on
November 30, 2016
13. Egypt: Article 2.3 of the Law No. 82 of 2002 on the Protection
of Intellectual Property Rights, enacted on June 1, 2002
14. El Salvador: Article 107(c) Law on Intellectual Property
enacted on July 14, 1993, as amended up to Legislative Decree No.
611 of February 15, 2017
15. Estonia: Section 7.2 of the Patents Act enacted on March 15,
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1994, consolidated text of January 1, 2015
16. European Union: Article 53(c) of the European Patent
Convention (16th edition) published on June 2016
17. France: Article L611-16 of the Intellectual Property Code
enacted on June 30, 1992, consolidated version of March 17, 2017
18. Georgia: Article 17(b) of the Law No. 1791 enacted on
February 5, 1999, as amended up to Law No. 3031 of May 4, 2010
19. Germany: Section 2(a)1 of the Patent Act, as amended up to Act
of October 8, 2017
20. Ghana: Section 2(c) of the Patent Act 2003 enacted on
December 30, 2003
21. Guatemala: Article 92(a) of the Industrial Property Law enacted
on September 17, 2000
22. Honduras: Article 5.9 of the Industrial Property Law enacted on
December 29, 1999
23. Iceland: Article 1 of the Patents Act No. 17/1991, as amended
up to Act No. 126/2011
24. India: Article 3(i) of the Patents Act enacted on September 1970
and as amended up to April 2005
25. Indonesia: Article 7 of the Law of the Republic of Indonesia
No. 13 on Patents enacted on July 28, 2016
26. Israel: Article 7 of the Patent Law, 5727-1967, consolidated
version of 2014
27. Jordan: Article 4(c) of the Law No. 32 of 1999 on Patents,
enacted on September 19, 1999
28. Kenya: Article 21.3(c) of the Industrial Property Act 2001 (Act
No. 3 of 2001), as amended up to Act No. 11 of 2017
29. Lebanon: Article 3.3 of the Law No. 240/2000 of 2000 on
Patents, enacted on August 6, 2000
30. Lithuania: Article 2 of the Law No. I-372 of January 18, 1994,
on Patents, as amended by Law No. X-1119 of May 10, 2007
31. Malaysia: Article 13(d) of the Patents Act 1983, enacted on
1983 as amended up to August 2006
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32. Malta: Article 4.4 of the Patents and Designs Act (Chapter 417),
enacted on May 31, 2002
33. Mauritius: Article 11.3(c) of the Patents, Industrial Designs and
Trademarks Act 2002 enacted on July 1, 2002
34. Mexico: Article Art. 19.VII of the Industrial Property law
enacted on June 1991, consolidated text published in the Official
Journal of the Federation on March 13, 2018
35. Montenegro: Article 7.2 of the Law on Patents enacted on July
15, 2015
36. Morocco: Article 24(b) of Law No. 17-97 on the Protection of
Industrial Property enacted on February 14, 2000, as amended by
Laws No. 31-05 and No. 23
37. New Zealand: Article 16.2 of the Patents Act 2013 enacted on
September 12, 2013
38. Nicaragua: Article 7(b) of Law on Patents, Utility Models and
Industrial Designs (No. 354 of 2000) enacted on May 31, 2000
39. Norway: Section 1 of the Patents Act No. 9 enacted on
December 15, 1967, consolidated text of 2018
40. Panama: Article 14.7 of Law No. 35 enacted on May 10, 1996,
on Industrial Property
41. Papua New Guinea: Section 2 of the Patents and Industrial
Designs Act 2000 enacted on June 30, 2000
42. Paraguay: Article 4(e) of Law No. 1.630/2000 on Patents, as
last amended by Law No. 2.593/2005
43. Philippines: Section 22.3 of the Intellectual Property Code of
the Philippines (Republic Act No. 8293)
44. Poland: Article 29(iii) of the Industrial Property Act of June 30,
2000, as amended up to Act of July 24, 2015
45. Portugal: Article 53.3(c) of the Industrial Property Code, as
amended up to Law No. 46/2011 of June 24, 2011
46. Romania: Article 8(d) of Law No. 64/1991 on Patents (as
amended up to Law No. 83/2014)
47. Serbia: Article 9.2 of the Law on Patents No. 99/2011, enacted
on December 25, 2011
762 AM. U. INT’L L. REV. [34:4
48. Singapore: Section 16(2) of the Patents Act (No. 24 of 2001),
as amended by Act No. 2 of 2007
49. Slovakia: Article 6.1(c) of the Act No. 435/2001 Coll.,
consolidated version of 2009
50. Spain: Article 5.4 of the Law No. 24/2015 of July 24, 2015, on
Patents
51. Sweden: Article 1 of the Act (2004:159) Amending the Patents
Act (1967:837)
52. Switzerland: Article 2 of the Federal Act of June 25, 1954, on
Patents for Inventions, as amended up to January 1, 2017
53. Thailand: Article 9.4 of the Patent Act B.E. 2522 (1979), as
amended up to December 31, 1998
54. FYR Macedonia: Article 26 of the Law on Industrial Property
enacted on January 11, 2009
55. Seychelles: 6.1(e) of the Industrial Property Act 2014 enacted
on April 15, 2014
56. Trinidad and Tobago: Article 12.1(d) of the Patents Act, 1996
enacted on December 31, 1995
57. Tunisia: Article 2(d) of the Law No. 2000-84 of August 24,
2000, on Patents
58. United Kingdom: Article 4A of the Patents Act 1977, as
amended by the Patents Act 2004
59. Uganda: Article 8.3(c) of the Industrial Property Act, 2014,
enacted on January 5, 2014
60. Uruguay: Article 14(a) of Law No. 17.164 of September 2,
1999, regulating Rights and Obligations relating to Patents, Utility
Models and Industrial Designs
61. Vietnam: Article 59.7 of the Law No. 50/2005/QH11 enacted
on November 29, 2005, on Intellectual Property
62. Zambia: Article 17(a) of the Patents Act 2016
